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Abstract 
 The aggregation of amyloid-beta (Abeta) is implicated in the etiology of Alzheimer’s 
disease (AD). Aggregation in vivo permits interactions with transition metal ions and lipids of 
the cell membrane. Abeta-metal interactions are suggested to induce metal ion dyshomeostasis 
and promote oxidative stress while Abeta-membrane interactions catalyze the formation of 
specific oligomers which destabilize and permeabilize the lipid bilayer. Oxidative stress may 
also modulate bilayer integrity through acyl chain peroxidation which causes membrane 
thinning. The structural and mechanistic effects of these interactions on the aggregation of Abeta 
remain unclear. Multiple glycosidic polyphenol natural products and their esterified derivatives 
were investigated for their ability to function as molecular probes against metal-Abeta. The 
interactions between Abeta and thin model membranes were also investigated through a 
combination of NMR spectroscopy, fluorescence spectroscopy, and atomic force and 
transmission electron microscopies. 
 The natural products Phlorizin, Verbascoside, and Rutin were all evaluated for their 
ability to modulate metal-Abeta aggregation. Verbascoside effectively inhibited aggregation 
while its esterified derivative, VPP, showed similar efficacy in vitro. Both compounds were also 
capable of disaggregating preformed fibrils, though they bound to both the monomeric and 
fibrillar forms of Abeta through distinct mechanisms. Esterification greatly reduced VPP’s 
ability to inhibit metal-Abeta cytotoxicity, however. 
xi 
 
 Subsequently, the interaction and aggregation of Abeta with both thick (DOPC or POPC) 
and thin (DLPC) model membranes was evaluated. tr-NOESY and relaxation based NMR 
experiments probed monomer interaction on the bilayer surface; folding was conserved 
regardless of bilayer thickness, suggesting that the preliminary interaction is exclusively driven 
by surface contacts. Additionally, the work provides the first experimentally derived structural 
constraints for membrane-associated Abeta. The progression of Abeta from its conserved, folded, 
monomeric state to its aggregated state was monitored in the presence of thick and thin 
membranes. DLPC bilayers uniquely stabilized membrane associated oligomers while 
simultaneously destabilizing the bilayer. DLPC also remodeled preformed fibrils into a pseudo-
unfolded state which resembles protofibrillar aggregates.  
 These results provide a new reagent with potential applications as a probe against metal-
Abeta in vitro and insights into early structures of membrane-associated Abeta and mechanisms 
by which membrane structure can modulate the Abeta aggregation.   
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Chapter 1 
Introduction to Proteins, Metals, and Membranes in Alzheimer’s Disease 
Portions of this chapter were adapted from the following publications: 
 Lee, H. J., Korshavn, K. J., Kochi, A., Derrick, J. S., Lim, M. H. Cholesterol and Metal 
 Ions in Alzheimer’s Disease. Chem. Soc. Rev. 43, 6672-6682 (2014); Beck, M. W., 
 Pithadia, A. S., DeToma, A. S., Korshavn, K. J., Lim, M. H. in Ligand Design in 
 Medicinal Inorganic Chemistry, Storr, T., Ed.; John Wiley & Sons, Ltd: Chinchester, 
 West Sussex, 2014, 257-286. 
1.1. Introduction to Alzheimer’s disease 
 In November of 1906, Dr. Alois Alzheimer first presented the case of a 50 year old 
female patient who had presented paranoia, sleep disruptions, memory loss, and mood changes. 
Upon examining the brain of this patient postmortem, he observed the presence of proteinaceous 
aggregates with in the brain’s histology.1 This marked the first discussion of a disease which now 
bears its discoverer’s name, Alzheimer’s. In the 110 years since this initial discussion, 
Alzheimer’s disease (AD) has become one of the most widely recognized mental disorders to the 
lay public. As of 2015, an estimated 46.8 million individuals were believed to be living with AD 
worldwide; it is expected that the number of afflicted individuals will increase to at least 130 
million by the year 2050.
2
 Within the United States of America, between 2000 and 2013, deaths 
caused by AD have increased by 71%, from 17.6 individuals per 100,000 in 2000 to 26.8 
individuals per 100,000 in 2013 (Fig. 1.1).
3
 In contrast, the five other leading causes of death, 
breast cancer, prostate cancer, heart disease, stroke, and HIV, have all seen their mortality rates 
decrease over the same time period (Fig. 1.1b). Despite over a century of research into the  
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Figure 1.1. Mortality rates associated with AD. (a) The death rate associated with AD has 
gradually increased since 2000. (b) From 2000 to 2013, of the 6 leading causes of death in the 
United States, only AD has seen an increase in disease associated deaths. Figures adapted from 
reference 3.  
 
causes, effects, and potential treatments of AD, we remain unable to effectively regulate the 
disease. 
1.2. Molecular pathology of AD 
 A major hindrance to the development of effective therapeutics against AD progression 
and death is the complex pathology which underlies the disease. This complexity has obfuscated 
the identification of a singular mechanism by which neuronal damage and death occur in AD and 
has subsequently prevented the development of effective and targeted biological or chemical 
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interventions. Due to the initial observation by Dr. Alzheimer of proteinaceous aggregates in the 
brains of diseased patients, AD is commonly discussed as a protein folding disease, involving 
both the peptide amyloid- (A) found within senile plaques and hyperphosphorylated tau 
protein observed in neurofibrillary tangles.
4-6
 Along with the misregulation of protein folding, it 
has also been suggested that metal ion dyshomeostasis may be culpable in AD-related toxicity; 
defects in metal ion regulation have also been suggested to foster and environment of heightened 
oxidative stress in the brain.
7,8
 Disruption of neuronal lipid bilayers, caused by protein 
dyshomeostasis, has also been suggested to facilitate cellular death.
9
 Finally, it was proposed that 
reductions in the levels of the neurotransmitter acetylcholine could be causative in AD 
progression.
10,11
 While most current FDA approved drugs against AD are targeted against this 
hypothesis, it has become more widely accepted that this misregulation is the result of disease 
progression, as opposed to causative.
10-12
 With the multitude of pathways implicated in cellular 
malfunction in AD, it is unsurprising that an effective therapy continues to be elusive. While it 
remains to be seen what role each of these individual mechanisms plays in disease pathogenesis 
and progression, consensus is growing that many of these factors and pathways are interrelated. 
The modulation of one may result in changes in others aspects of the disease as well, and 
therapeutically targeting a single pathway may be minimally efficacious.
4,6,7,9,13
 
1.2.1. Amyloid hypothesis of AD 
 As one of the two protein aggregates initially observed in the brains of AD patients, A 
was associated very early on with AD pathogenesis.
6,13
 The implication of A as a key 
component of AD related neurotoxicity rose to prominence with the introduction of the amyloid 
cascade hypothesis first proposed in the early 1990s.
14,15
 A, encompassing a variety of peptide 
isoforms ranging from 38 to 43 residues, results from the proteolysis of the transmembrane 
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amyloid precursor protein (APP) by - and -secretase enzymes (Fig. 1.2a).4,6,13 However, APP 
is also capable of creating a non-amyloidogenic, truncated peptide when it is cleaved by -
secretase instead of -secretase. Despite the many isoforms of A which have been observed, the 
40 and 42 residue isoforms are the most prevalent in the brains of AD patients.
6,13
 It is also 
thought that A42 is the more toxic of the two predominant species while A40 is the most 
common product of APP cleavage.
4
  
 As a monomeric peptide, A is relatively inert and non-toxic; it has been proposed that 
A may possess some neuroprotective functions, though the extent of these protective roles 
remains controversial.
16-18
 It is suggested that A only enacts its toxic function during and after 
its transformation into an amyloidogenic fiber.
4,6,13,19
 Like other amyloid forming peptides and 
proteins, A is proposed to undergo a nucleation dependent polymerization mechanism to form 
amyloid fibrils(Fig. 1.2b).
20,21
 In this aggregation pathway, monomers interact to form small 
oligomers. These oligomers then combine with each other and/or monomeric subunits to 
generate larger oligomers, eventually forming a large protofibrillar species. Once the protofibril 
is generated, it is able to rapidly elongate and generate mature fibrils.
21
 These fibers are able to 
subsequently fragment into shorter segments which are capable of catalyzing additional 
elongation and subsequently generate additional fibrils.
22
 While the initial amyloid hypothesis 
has suggested that the end stage fibrils were the principle toxic species, a more recent shift 
within the field now posits that intermediate oligomers are the culprit.
14,19,23
 It remains unclear, 
however, at what point these purported toxic oligomers are formed during aggregation. It is 
possible that they are either on pathway towards aggregation or off-pathway variants that result 
from improper amyloid formation.
23
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 A leading hindrance to better understanding the identity and function of toxic A 
oligomers is a lack of structural insight into distinct oligomeric species. The monomeric state of 
A is well established to be predominantly unstructured and random coil, though some studies 
have identified a lowly populated partially helical structure in solution which can be stabilized by 
the presence of detergents (Fig. 1.2c).
24-27
 The end stage fibrils are also well characterized due to 
their extreme stability.
28-33
 The wealth of structural data has revealed the ability of A to 
generate a variety of stable polymorphs which depend on the peptide isoform and the 
aggregation conditions (Fig. 1.2d).
34
 It remains unclear, however, how end stage fiber 
polymorphism is controlled by aggregation conditions and whether the intermediates formed on 
the way to distinct polymorphs are similarly unique or whether polymorphism is only dictated at 
the end of A aggregation. Meanwhile, the relatively transient nature of intermediate oligomers 
has rendered them a black box; while it is known that they exist and that there are varieties, 
details about the kinetics of their formation or their structure are unknown for the most part.  
 Some initial investigations have begun to probe oligomer structure, though they often 
rely on low resolution techniques or additional chemical modification to stabilize the 
intermediate species. Conformation specific antibodies have provided the most rudimentary tool 
to distinguish amyloid aggregate structures.
35
 A11 is capable of binding globular, prefibrillar 
oligomers while OC binds to the cross-strand structure common to many amyloids.36,37 While 
these tools are useful in histological examination and some high throughput studies, they lack 
insight at the molecular level. Methods such as AFM have had better luck at distinguishing 
distinct oligomeric species. While molecular dynamics (MD) simulation has been used to 
augment these investigations, there is still little experimental data exploring the atomic resolution 
of oligomeric structure.
38
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 Higher resolution methodologies such as crystallography and NMR have had recent 
success in providing constraints on some unique oligomeric species. Crystallographic 
investigations continue to require short peptide fragments, however, and predominantly generate 
fibrillar or prefibrillar structures.
34,39-41
 NMR based studies, meanwhile, benefit from their ability 
to utilize full length A peptide. However, these studies require extremely high concentrations of 
peptide to generate their stable intermediates, raising questions about the relevance of the 
observed intermediates and whether they are the result of traditional amyloid aggregation or are 
the result of artificially high peptide concentration.
42,43
 These preliminary investigations of A 
oligomers emphasize the technical difficulty which accompanies the study of lowly populated 
and transient oligomeric states. What is more, these studies show that the potential oligomers 
likely possess a diversity similar to that already observed in end stage fibers, which poses a great 
challenge to the community as it works to fully characterize the aggregation of A from its 
freshly cleaved, monomeric state all the way to its terminal fiber. It should also be noted that the 
majority of these structural studies exploring the monomer, intermediate aggregates, and fibrils 
all occur in vitro and, almost always, in the absence of additional biomolecules. It is known that 
A interacts with a variety of other molecules in vivo and that these interactions are capable of 
further modulating the aggregation of A.6,7,9,44,45 Investigations of the impact of these 
heterogeneous environments are occurring in parallel with the studies of A alone described 
above. 
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Figure 1.2. Amyloid formation by A. (a) Monomeric A is derived via the proteolytic cleavage 
of the transmembrane protein APP. Cleavage by - and -secretase produces the full length, 
amyloidogenic peptide. A lack of specificity in -secretase cleave is partly responsible for the 
generation of various isoforms like A40 and A42. (b) After monomeric A is generated, it 
undergoes a nucleation-dependent polymerization reaction to eventually form fibrils. During its 
aggregation, it is able to form both on- and off-pathway aggregates whose presence and structure 
is dependent upon solution conditions. (c) While monomeric A is traditionally considered an 
intrinsically disordered peptide, devoid of structure, solution NMR studies have observed 
structured species in solution as well as in the presence of the detergent SDS.
25,26
 (d) Amyloid 
fibrils have an array of polymorphs which are dependent upon their solution conditions as well 
as their sequence. Variations in both their C-terminal sequence and mutations such as the Osaka 
mutation (E22) can dramatically alter the final structure.30-32 
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1.2.2. Metal ion hypothesis of AD 
 Just as proteostasis is proposed to be disrupted in AD due to the aggregation of A and 
hyperphorphorylated tau protein, so too are metal ions suggested to be misregulated.
4,7
 Metals 
serve a wide range of functions within the brain, including acting as secondary messengers in 
cellular signaling, stabilizing protein structure, acting as enzymatic cofactors, and transporting 
dioxygen (O2).
7,46,47
 Within AD, however, metal ions such as Zn(II), Cu(I/II), and Fe(II/III) enter 
a state of dyshomeostasis. In this diseased state, metal ions become miscompartmentalized and 
the cell is susceptible to entering a state of heightened oxidative stress.
7,46
 The altered 
distribution of metals can induce non-native conformations in metalloproteins and deactivate 
metalloproteins through a loss of metal active sites or cofactors.
4,7,48,49
 Loss of functional native 
proteins, such as the antioxidants Cu/Zn superoxide dismutase (SOD1) and cytochrome c 
oxidase (CcO), coupled with the coordination of redox active metals like Cu(I/II) and Fe(II/III) 
in non-native environments is also capable of generating reactive oxygen species (ROS) and 
promoting oxidative stress.
7,47
 The increased presence of ROS may, in turn, promote oxidative 
damage of both proteins and lipids which further destabilizes proteins and the cellular 
membranes.
4,7,50,51
 Prolonged exposure to oxidative stress is damaging to the mitochondria and 
one mechanism by which metal ion dyshomeostasis is capable of directly mediating cellular 
death in AD.
52,53
 
 Along with disrupting normal functions within the brain, aberrant metal behavior is 
capable of exacerbating the aggregation of A.4,7,13,44,54 The transition metal ions Zn(II), Cu(I/II), 
and Fe(II/III) were all observed to be present in the senile plaques of AD patients at 
concentrations 3-5 times higher than the sounding tissue.
54,55
 Subsequent in vitro studies have 
shown that all three metals can coordinate with A, generating metal–A complexes; 
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furthermore, it has been suggested that coordination of A to either Cu(I/II) or Zn(II) can alter 
the aggregation of the peptide (Fig. 1.3).
4,7,46
 The redox inactive Zn(II)-A complex is 
coordinated through either four or six donor atoms originating from histidine side chains and 
amide backbone heteroatoms within the first sixteen residues of the peptide sequence.
44,56
 The 
coordination of Cu–A is dynamic and pH dependent.7,46,57 The predominant coordination at 
physiologically relevant pH (i.e., 7.4) for Cu(II) is 3N1O (three nitrogen donor atoms and one 
oxygen donor atom; believed to be His6, His13/14, N-terminal amine, and Asp1 carboxylate) 
while Cu(I) adopts a 2N (two nitrogen donor atoms; suggested to be His13 and His14) 
coordination sphere.
58
 Along with altering the aggregation of A, Cu–A species have a redox 
potential = 0.30 V versus normal hydrogen electrode (NHE).
7,46,58
 Few structural studies have 
been reported for iron coordination to A due to the propensity of Fe(II) to oxidize to Fe(III) and  
 
Figure 1.3. Metal ion coordination by monomeric A. Monomeric A is able to coordinate to (a) 
Zn(II), (b) Cu(I), (c) Cu(II), and (d) Fe(II) via the first 16 residues of the sequence. Current 
estimates for the affinity of the complexes range from high nM to low pM.
7,44,46
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precipitate as Fe(OH)3 and other complexes.
58
 Preliminary results propose that Asp1, Glu3, and 
His6/13/14 may be involved in Fe(II) coordination by A.58 Like CuA, FeA is redox active; 
in the A–iron–nitriloacetic acid complex the redox potential was measured to be 0.23 V versus 
NHE.
59
 
1.2.3. Membranes and A in AD 
 As a disease of systemic dyshomeostasis and perturbation, AD extends beyond the 
changes in protein folding and metal ion distribution discussed above and disrupts many aspects 
of cellular metabolism.
60,61
 Lipid metabolism is particularly impacted.
62-65
 Because lipids play a 
crucial role in maintaining cellular homeostasis across the neuronal bilayer, facilitate the 
transport of materials throughout the cell, and  mediate the production and aggregation of A 
their modulation has wide ranging impacts on AD pathology.
64-66
 
  Many toxic mechanisms have been proposed for A aggregates in AD.23 A prominent 
model proposes that the interaction of various A aggregates with the surface of the neuronal 
membrane is capable of disrupting bilayer integrity.
9,65
 Ionic depolarization across neuronal 
bilayers has long been associated with AD which implicates a potential pathway of membrane 
permeabilization.
67,68
 A structural basis for these toxic interactions remains unclear, however. 
Studies have suggested that A is capable of forming pore-like structures which span the 
neuronal bilayer and facilitate the influx of Ca
2+
.
68-70
 Such pores have been detected for both 
A40 and A42, the Osaka mutant A40(E22) as well as a D-enantiomer sequence of A40 which 
suggests a highly conserved aggregation intermediate.
68,69,71-73
 Common to many of these 
observed channels is a specificity to Ca
2+
; other metal ions, such as Zn
2+
 and  Al
3+
, are unable to 
traverse these channels while also blocking the influx of Ca
2+
.
68,69,73
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 The transient and inhomogeneous formation of these proposed pore-like structures has 
made them difficult to characterize structurally. Atomic force microscopy (AFM) based 
measurements have observed pore like structures on synthetic bilayers which vary in their size 
and subunit arrangement.
38,74,75
 MD simulations based around these observed pores, coupled 
with solid-state NMR structures of the cross--strand fiber structures, have produced initial -
barrel models which seek to explain the formation of these transmembrane pores.
38
 These models 
are incomplete, however, because they base their structural modeling on the assumption of a -
strand peptide with minimal experimental evidence. More recent exploration of membrane-
associated A aggregates has observed another -barrel structure by NMR using peptide trapped 
in detergent micelles.
76
 While this lends credence to the ability of A to form -barrels in 
hydrophobic environments, the use of detergent-based membrane mimetics reduces the value of 
comparing the NMR-based model with that derived from AFM performed on bilayers. 
Additional exploration is certainly required to better define the structural arrangement of 
membrane-associated A pores. 
 Accompanying pore formation, large scale membrane permeabilization has been reported 
to result from A aggregation on the lipid bilayer surface.69 As opposed to pore formation which 
allows the specific influx of Ca
2+
, membrane permeabilization results in the unconstrained transit 
of both ions and larger biomolecules across the membrane. In this way, the cell is not just 
depolarized, but loses all internal equilibria. Combined, these two distinct modes of disruption 
pose a two-step mechanism by which lipid bilayers may be permeabilized (Fig. 1.4). It remains 
unclear whether pore formation must precede membrane disruption or if the two mechanisms are 
decoupled from each other.
69
 Additionally, while pore formation has been found to be a 
consistent mechanism across various peptide sequences and membrane model systems,  
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Figure 1.4. Modes of membrane disruption by A. A is able to interact with lipid bilayers 
through a variety forms. Disruption by aggregates has been proposed to predominantly occur 
through pore formation and fiber-associated permeabilization.
69
 
 
membrane permeabilization by A has been suggested to be specific for bilayers which contain 
the lipid GM1 ganglioside within in vitro model systems.
69
 This requirement does not preclude 
permeabilization from occurring in vivo. GM1 ganglioside is known to incorporate into lipid 
rafts and GM1 ganglioside clusters while fulfilling a variety of functions within cellular 
bilayers.
77
 Additionally, A oligomers have been isolated from mouse interstitial fluid which 
contain stabilized GM1 ganglioside clusters. 
78
 Coupled with in vitro results suggesting that 
GM1 gangliosides are able to specifically catalyze toxic modes of A aggregation, it suggests 
that GM1 is able to play a crucial physiological role in the membrane-associated aggregation of 
A.45 Thus, while the general aggregation pathways of A in solution are dependent upon the 
isoforms of peptide, aggregation upon lipid bilayers is seemingly equally dependent upon the 
bilayer composition. This complicates the search for structural and mechanistic insights into the 
roles of membrane-mediated A aggregation in AD. Not only must all relevant peptide 
sequences be interrogated, but relevant lipid bilayer compositions must also be considered. 
 
1.3. Molecular probes of amyloid misfolding 
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 Current therapeutic interventions against AD provide temporary symptomatic relief; the 
five USA Food and Drug Administration (FDA) approved compounds for AD treatment are 
either acetylcholinesterase (AChE) inhibitors or N-methyl-D-aspartate (NMDA) receptor 
inhibitors (Fig. 1.5).
7,20,79
 Meanwhile, therapeutics targeting what are believed to be the causative 
aspects of AD have experienced limited clinical success.
80-84
 While potential drugs fail in clinical 
trials for a variety of reasons, it seems likely that AD therapeutics often fail due to a lack of 
understanding regarding the underlying molecular pathologies.
67,83,84
 Thus, the development of 
tools which are capable of interrogating individual aspects of AD, such as amyloid formation or 
metal ion dyshomeostasis, as well as multifunctional tools which are capable of simultaneously 
exploring the link between pathological factors is beneficial.
85-93
 Through the application of 
molecular probes it may be possible to better identify viable sites for therapeutic intervention 
within AD.   
 
Figure 1.5. FDA approved drugs for the treatment of AD. Four currently approved therapeutics 
act as AChE inhibitors: donepezil, rivastigmine, galantamine, and tacrine. Memantine acts as an 
NMDA inhibitor.  
 
1.3.1. Chemical modulators of amyloid aggregation 
 While it is highly advantageous to develop chemical agents capable of selectively 
modulating the aggregation of A, the identification and characterization of such tools is a 
daunting task. Amyloid formation by A can be modulated by a variety of chemicals common to 
protein biochemistry, including detergents, like sodium dodecyl sulfate (SDS), and chemical 
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denaturants, such as guanidinium chloride.
26,76,94-99
 These reagents are extremely non-selective in 
their action, however. They are capable of intervening at many different steps in the aggregation 
of A, are non-selective for A aggregation, and are unsuitable for application in in vivo 
systems. Thus, the development of specific molecular and biomolecular tools is essential.
100
 
1.3.1.1. Peptide-based tools 
 Early exploration of molecular modulation of A aggregation took advantage of the self-
recognition sequence in the middle of the A sequence.89 It is known that A16-20 (KLVFF) acts 
as a nucleating site for early aggregation events towards fibrillation.
4,89
 It was observed that the 
pentapeptide derived from this central sequence is capable of inhibiting fibril formation by full 
length A40 and A42.
101,102
 However, because the pentapeptide was derived from the 
amyloidogenic sequence of full length A the truncated construct was also capable of forming 
fibrillar structures, though the kinetics of their formation are much slower than for A40 and 
A42.
101,103
 Based on this initial success, peptide variants have subsequently been explored. 
Proline mutations were scanned through fragments of the central sequence of A, and the 
substitutions were observed to reduce the propensity of the peptide to form fibrillar aggregates 
while maintaining the ability to modulate fibrillation by full length A.104,105 The mechanistic 
success of peptide fragments as amyloid modulators has spurred advances in stabilized peptides 
and peptidomimetics which have the advantage of increased stability and bioavailability in 
vivo.
106,107
 Cyclization of the KLVFF sequence generated a more stable variant of the fragment 
which successfully stabilized small oligomers of reduced toxicity.
108
 The appendage of the 
KLVFF sequence onto a branched dendrimer framework similarly increased the reagent’s 
stability while maintaining the anti-amyloidogenic activity of the sequence.
109
 The overall 
success of these peptide-based tools has led to the development of a whole class of reagents 
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termed -sheet breakers which have subsequently been implemented in a variety of amyloid-
related protein folding problems.
89,110
 While these -sheet breakers initially were peptide 
sequences exclusively, they are now a mix of both peptide-based and small molecule tools.
110
 
1.3.1.2. Natural products 
 Small organic molecules offer an attractive alternative to peptide-based molecular tools; 
they possess an enhanced diversity of chemical space and can be more readily synthetically 
modified to improve various aspects of function. The lack of structural information regarding 
points of interest at which small molecules may intervene in A aggregation makes natural 
products attractive; these compounds can be readily screened to identify effective hits without a 
need for well characterized targets which are traditionally required for rational design of 
synthetic molecules. Natural products possess a range of stable scaffolds which have been shown 
to effectively modify a variety of biological systems, including enzyme activity, protein-protein 
and protein-DNA interactions, and membrane protein function.
111
 Additionally, because they are 
derived from natural sources, small molecule natural products often exhibit improved 
pharmacological characteristics, improved absorption, and reduced inherent toxicity relative to 
their synthetic counterparts.
111
 
 Polyphenolic compounds have become a leading class of small molecules in the study of 
A modulation (Fig. 1.6).112,113 Curcumin, a prototypical polyphenol derived from turmeric, has 
been reported to possess a wide range of beneficial properties, including an ability to block 
amyloid formation.
114,115
 When incubated with monomeric A, curcumin prevents the formation 
of soluble oligomers in vitro and decreases amyloid plaque load in AD model APP transgenic 
mice in vivo.
114
 It is believed that curcumin successfully inhibits fibrillation, in part, through 
interaction with C-terminal residues which subsequently prevents the formation of the D23-K28 
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salt bridge responsible for stabilizing the cross -strand structure of A fibrils.116 Resveratrol, a 
potent antioxidant found in red wine, has also been reported to reduce the toxicity of A 
species.
117,118
 Initially, it was suggested that the principle mode of protection was as an 
antioxidant and through reduction of the inflammatory response to the presence of A.117-119 
Along with this antioxidant behavior, resveratrol is capable of binding to both monomeric and 
aggregated forms of both A40 and A42 with dissociation constants (Kd) of 10-50 M.
120
 
Additionally, the association of resveratrol with monomeric A promotes the formation of non-
toxic, soluble oligomers.
121
 These results suggest that resveratrol is capable of modulating A 
associated toxicity through multiple distinct mechanisms. (-)-Epigallocatechin-gallate (EGCG), a 
polyphenolic extract from green tea, is a potent antiamyloidogenic compound with activity 
against a broad spectrum of aggregation-prone proteins and peptides.
122-126
 Along with inhibiting 
A fibrillation, EGCG is capable of remodeling preformed A fibrils, suggesting an ability to 
intervene at a variety of stages of aggregation.
123
  
 Despite the availability of these and other antiamyloidogenic natural products, they are 
not without their drawbacks. As observed in the study of resveratrol, many natural products are 
capable of interacting with a variety of proteins and multiple cellular processes. While these 
issues are minimized in simplified in vitro analysis of protein aggregation, it reduces the utility 
of the tools in cell-based and in vivo systems designed to investigate the broader functions of A 
aggregation.
113
 Additionally, the in vitro activity of polyphenolic natural products does not 
always translate to more complex systems due to a combination of small molecule instability and 
off target effects.
127
 Additionally, natural products often possess pharmacophores which are 
susceptible to oxidation (such as quinones and catechols) or covalent modification, obscuring the 
identity of the active molecule.
128
 Thus, while natural products provide a range of exciting and 
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valuable tools for the study of A aggregation, their applications are inherently limited in the 
absence of medicinal chemistry-inspired modifications. 
 
Figure 1.6. Antiamyloidogenic natural products. A variety of polyphenolic natural products, 
including curcumin, resveratrol, and EGCG, have demonstrated an ability to modulate the 
aggregation and toxicity of A in vitro and in vivo. 
 
1.3.1.3. Synthetic antiamyloidogenic small molecules 
 Given the limitations which both peptide and natural product amyloid inhibitors possess, 
synthetic small molecule modulators have also been extensively explored.
129,130
 Some of the 
early successes in synthetic small molecule probes were organic dyes due to their high solubility 
and stability and relatively low toxicity (Fig. 1.7a).
129
 Congo red has long been used in the 
histological detection of amyloid plaques in tissue.
131-133
 Exploring Congo red’s ability to bind to 
A aggregates, it was observed to block peptide fibril formation and subsequently block 
aggregate associated toxicity.
134,135
 It was also observed that, at low peptide concentrations, 
Congo red stabilizes monomeric A40 and prevents early oligomer formation in cell culture 
media.
136
 As the peptide and Congo red concentration are increased, the two are capable of 
forming small oligomeric complexes at a 1:1 ratio of peptide to ligand; the addition of higher 
concentrations of Congo red promotes larger oligomers with a peptide to ligand ratio of 1:2.
137
 
These stabilized oligomers are proposed to be off-pathway from conventional amyloid 
fibrillation. Orange G is another dye traditionally used to stain proteinaceous aggregates, and it  
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Figure 1.7. Non-natural organic small molecule modulators of A aggregation. (a) Organic dyes 
like Congo red, orange G, and methylene blue were some of the early probes of A amyloid 
formation. (b) High throughput screening has helped identify unexpected scaffolds like 
calmidazolium chloride, BAF1, and BAF11 which possess antiamyloidogenic activity. (c) With 
more recent understanding of the amyloid formation pathway, it has become possible to 
rationally select synthetic molecules like CLR01 and CLR03 which may possess unique 
modulatory behavior.
138
 
 
has been proposed to be a broad scope inhibitor of A aggregation.139,140 However, follow up 
studies revealed that, similar to Congo red, orange G inhibits the formation of fibrillar aggregates 
by stabilizing on pathway oligomers.
90
 Crystallographic analysis has revealed that orange G is 
also capable of binding to fibrillar A species through positively charged lysine residues, despite 
its inability to block fibril formation.
141
 Methylene blue is another dye which has found 
applications in a wide range of fields, serving as an antiseptic, chemotherapy agent, and 
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antibiotic among many other functions.
142
 Unlike Congo red and orange G, methylene blue has 
been proposed to inhibit oligomer formation while promoting fibrillation.
143
 Additionally, 
preformed A fibrils are susceptible to remodeling by methylene blue; they were observed to be 
converted into amorphous aggregates, suggesting that the fibrils promoted by the presence of 
methylene blue during aggregation differ from the fiber structure formed by free A in 
solution.
144
 The antiamyloidogenic activity of methylene blue has also been shown to be 
neuroprotective in a transgenic mouse model of AD.
145
 
 While the dyes described above have provided valuable insights into how A aggregation 
may be modulated, their applications have been driven more by their long history in histology 
and medicine than any structure- or mechanism-based rationale. The lack of defined structures 
along the amyloidogenic pathway of A makes conventional rational design of 
antiamyloidogenic small molecules difficult as there are few targets to base designs upon. 
However, screening approaches are able to provide valuable insight into pharmacophores which 
have value as specific amyloid inhibitors through a discovery-focused approach rather than a 
validation-focused approach as was used with the dyes (Fig. 1.7b). The Library of 
Pharmacologically Active Compounds (LOPAC) was screened for modulators by affixing fibrils 
to a plate and incubating the compounds with biotin-tagged A; the extent of fibrillation was 
subsequently measured with a streptavidin-europium fluorescent probe.
146
 The screen yielded no 
potent inhibitors of aggregation. However, one compound, calmidazolium chloride, was found to 
promote the formation of protofibrillar aggregates. The stabilized protofibrils were observed to 
be structurally distinct from conventional fibers formed in solution. Residues 22-29 were found 
to have increased structure and rigidity indicative of a unique polymorph.
146
 A small library of 
previously identified amyloid modulators was also evaluated to determine distinct mechanisms 
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of inhibition.
90
 From the small library, three distinct classes of modulators were observed. Class 
1 compounds destabilize oligomer formation but had no impact upon fibrillation by A. Class 2 
compounds were found to inhibit both oligomer and fiber formation. Class 3 compounds were 
found to block fibrillation but not oligomerization.
90
 Recent advances in both the understanding 
of amyloid fiber structure and in silico screening technologies have also facilitated computational 
analysis of small molecule probes against A aggregation.141,147-149 Following the in silico screen 
of ~18,000 distinct compounds, 25 hits were explored experimentally, and 5 were found to 
reduce the toxicity of A aggregates.150 Two of these active compounds, BAF1 and BAF11, bind 
to preformed fibrils with low M dissociation constants. It is proposed that this relatively tight 
affinity for the fibril stabilizes the end stage aggregate and decreases the concentration of toxic 
intermediate oligomers. 
 In parallel with repurposing known molecules and utilizing screening to identify 
functional amyloid modulators, rational selection and design of active molecules is expanding. A 
powerful example is the implementation of “molecular tweezers” (MTs) to specifically target 
charged lysine and arginine side chains of amyloidogenic sequences (Fig. 1.7c).
138,151
 The MT 
CLR01 and its truncated derivative CLR03 were both analyzed for their ability to inhibit a range 
of amyloidogenic peptides and proteins, including A40 and A42.
138
 While CLR01 was a potent 
inhibitor of aggregation by A40 and successfully attenuated the aggregation of A42, CLR03 
demonstrated no efficacy, suggesting that it was unable to engage the charged side chains. 
Additionally, CLR01 successfully decreased the toxicity of A aggregates in cell culture.138 A 
follow up study employing ion-mobility spectroscopy-mass spectrometry (IM-MS) found that 
CLR01 promoted the formation of small, compact oligomeric species while CLR03 promoted 
the formation of on pathway oligomers.
152
 CLR01 was also observed to inhibit A40 fibrillation 
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on lipid bilayers and the membrane perturbation associated with amyloid formation.
153
 Because 
of its efficacy against amyloid aggregation, the pharmacological impact of CLR01 was 
investigated and the compound was observed to be non-toxic with minimal side effects in mouse 
models. It was also observed to be blood-brain barrier permeable, showing promising signs as a 
lead candidate in therapeutic optimization.
154
 
1.3.2. Multifunctional small molecules against amyloid formation 
 While the development of antiamyloidogenic molecular probes continues, the 
multifactorial nature of AD makes it important to possess tools which can simultaneously 
interrogate multiple aspects of disease pathology.
4,7,155
 Towards this end, researchers have 
pursued multifunctional small molecules which are able to interact with multiple components 
associated with AD, including A aggregation, misregulated metal ions, and AChE 
inhibition.
85,86,155
 There are two primary approaches to the development of multifunctional small 
molecules. Two distinct pharmacophores which are known to modulate distinct aspects of AD 
biology can be connected via a short, flexible tether using the linkage approach. Alternatively, a 
moiety responsible for one mode of action can be installed within a functional framework known 
to regulate a second parameter through the incorporation approach (Fig. 1.8a).
155
 
 An early effort at a bifunctional metalA modulator was XH1 (Fig. 1.8b).156 Two 
molecules of a derivative of the amyloid binding dye thioflavin-T (ThT) were combined with a 
linker capable of metal chelation. XH1 was found to decrease Zn(II)A aggregation and 
decrease the amyloid plaque load in a PS1/APP transgenic mouse model which models AD 
pathology. Another bifunctional probe, Cyc-KLVFF, was designed by combining the cyclic 
metal chelator cyclen with the known -sheet breaker peptide sequence KLVFF.157 Similar to the 
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effect of XH1 on Zn(II)A, Cyc-KLVFF successfully attenuated the aggregation of Cu(II)A 
species while also reducing cellular apoptosis induced by toxic Cu(II)A aggregates. 
 
 
Figure 1.8. Multifunctional ligand design. (a) Multifunctional probes may be developed by 
combining frameworks which individually interrogate a single aspect of AD pathology using a 
flexible linker (linkage approach) or by incorporating one pharmacophore into the framework of 
the other. (b) XH1 and Cyc-KLVFF are metalA probes generated using the linkage approach 
while clioquinol, L2-b, DPP2, and ML were all produced using the incorporation method. (c) 
Hybrid 5 was developed to simultaneously interact with metalA species and modulate AChE 
activity. 
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 The incorporation method has also produced a range of effective metalA 
modulators.
85,86,155
 L2-b was initially developed by installing a metal chelation moiety similar to 
that found in the metal chelator clioquinol into the stilbene framework common to imaging 
agents used to interrogate plaque load in vivo (Fig. 1.8b).
158-160
 L2-b was observed to 
successfully attenuate the aggregation of both Cu(II)A and Zn(II)Aand rescued cell 
viability that was decreased as a result of metal-A aggregation. Additionally, it was found that 
the inclusion of the dimethylamino moiety in L2-b was important for the framework’s 
function.
158
 Another bifunctional probe, DPP2, was developed using a similar approach as was 
employed in the design of L2-b; the diphenylpropynone scaffold, a known A binding agent, 
was equipped with a bidentate metal chelation moiety.
155,161
 Like L2-b, DPP2 successfully 
modulated the aggregation of both Zn(II)and Cu(II)A. Unlike L2-b, however, DPP2 was 
toxic to cells, likely due to its ability to act as a Michael acceptor. This suggests that DPP2 is 
best suited as an in vitro probe of metal associated protein aggregation while L2-b has more 
promise as an in cell or in vivo probe.
162
 A more recent advance in multifunctional A 
modulation is the ligand ML.
163
 The stilbene framework used in the development of L2-b was 
coupled with L2-b itself to promote metalA interaction while also expanding the metal 
chelation ability via the addition of two additional donor atoms. The tetradentate metal binding 
was also suggested to have antioxidant capabilities by reducing the redox cycling of chelated 
metal ions. It was observed that ML effectively modulates the aggregation of A both in the 
presence and absence of metal ions while reducing the toxicity of a range of A aggregates and 
functioning as a potent antioxidant. The success of ML suggests that our understanding of A 
aggregation and its interaction with the molecular pathologies of AD has expanded to a point 
where rational design of modulators is possible, though still difficult. 
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 This progress is further evident in the trifunctional compound Hybrid 5 which is capable 
of modulating metalA and AChE activity (Fig. 1.8c).164 In order to generate Hybrid 5, the 
metal-A modulator L2-b was combined with a derivative of the FDA approved AChE inhibitor 
tacrine. Despite the presence of the linker, Hybrid 5 possessed stronger AChE inhibition 
behavior than tacrine. Hybrid 5 also maintained its ability to modulate both Zn(II) and 
Cu(II)A aggregation while successfully inhibiting the aggregation of metal-free A in 
solution. While tacrine has fallen out of favor clinically due to extreme hepatotoxicity, the in 
vitro success of Hybrid 5 suggests that it is possible to generate compounds which 
simultaneously modulate multiple, unassociated aspects of AD molecular pathology.
165
 This 
holds great promise for the immediate development of molecular probes and the eventual 
generation of more efficacious therapeutic interventions. 
1.4. Methods to investigate aspects of A aggregation 
 Due to the highly heterogeneous nature of A aggregation, it is essential to possess a 
technical toolbox which contains a wide range of methodologies and probes capable of 
characterizing aggregating species that span from the monomeric peptide up to the mature fibril 
and all intermediates in between. A prominent probe of the amyloid community is the amyloid-
specific dye ThT.
97
 ThT fluorescence increases based on the presence of -strand structures in 
solution and provides indirect evidence of fibril formation.
166,167
 With recent advances in kinetic 
modeling based on ThT-based aggregation monitoring, it is also now possible to infer a variety 
of mechanistic distinctions which provides insight into potential intermediate aggregate steps.
168-
170
 Despite the prevalence of ThT in the field of amyloid research it still suffers from a number of 
limitations. Because of its charge, ThT preferentially interacts with charged surfaces and is 
therefore susceptible to changes in solution pH.
171
 Additionally, it has been demonstrated that 
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small molecule modulators of amyloid formation sometimes possess fluorescence profiles which 
overlap with that of ThT or are capable of competing with ThT for the same binding site, 
resulting in dye displacement and a reduction in fluorescence despite no structural alteration.
172-
174
 Finally, some peptide sequences form fibers which are incapable of binding to ThT, a 
deficiency that can be induced by both polymorphic idiosyncrasies and intrinsic charge 
repulsion.
175,176
 Given these restrictions inherent to ThT assays, fluorescence analysis is often 
coupled with circular dichroism spectroscopy (CD).
177
 CD is able to confirm the fibrillation that 
is observed as a result of ThT fluorescence increases, but it is also capable of distinguishing non-
fibrillar changes in structure. Helical intermediates of A have been observed in the presence of 
negatively charged lipid bilayers while helical species of amylin, an amyloidogenic peptide 
associated with type II diabetes, have been stabilized by the presence of a synthetic derivative of 
curcumin.
178,179
 These non fibrillar states are invisible to ThT and thus highlight the 
complimentary power of CD.  
 Both static and dynamic light scattering (SLS and DLS, respectively) are able to further 
distinguish distinct aggregation intermediates, though become less useful as the heterogeneity of 
the sample increases or extremely large particles form.
180,181
 Both of these limitations are 
common in the later stages of amyloid formation making these tools best suited for the 
investigation of early oligomeric species. Aggregate size can also be estimated through either 
size exclusion chromatography (SEC) or analytical ultracentrifugation (AUC) though these 
disruptive techniques do not allow for high temporal resolution and can disrupt transient 
oligomeric complexes.
182,183
 Large aggregates, intractable by SLS, DLS, or SEC can be 
monitored and quantified through both transmission electron microcopy (TEM) and atomic force 
microscopy (AFM) as complimentary methods. Negative stain TEM, which relies on contrasting 
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stains, is capable of distinguishing aggregate sub-types while cryogenic TEM (Cryo-EM) has 
made advances in determining atomic level structures of model amyloid fibrils.
184-187
 AFM is 
similarly able to quantitatively distinguish amyloid fibril polymorphs while also being capable of 
monitoring a single sample over time with minimal disruption.
188,189
 
 Higher resolution structural insights are capable through the application of IM-MS. 
Advancements in ion-mobility spectrometry, initially used to study single subunit proteins, have 
enabled the study of much larger protein complexes.
190-193
 Because of this ability, IM-MS is an 
ideal tool for the investigation of amyloid peptide structure and organization. The sensitivity of 
collisional cross-section measurements to modest shifts in monomer structure due to small 
molecule and metal interactions has made it a valuable method for the characterization of early 
folding changes both on and off the pathway of amyloid formation.
194,195
 IM-MS has also proven 
powerful at identifying unique oligomeric intermediates which occur during the lab phase of 
amyloid formation.
196-198
 The ion-mobility component allows multiple oligomers of the same 
mass to be distinguished and has helped to identify some potentially key on pathway oligomeric 
intermediates for amyloid formation by A.196 When coupled with computational modeling and 
MD simulation, IM-MS is capable of providing high resolution insights into potential structural 
changes underlying amyloid formation. However, the lack of atomic level experimental 
constraints within these measurements makes complementation with additional biophysical tools, 
such as NMR and crystallography, advantageous. 
 As detailed earlier, end stage amyloid fibers are the most structurally well characterized 
A aggregate. The extreme stability of mature fibers makes them ideal candidates for rigorous 
characterization by solid-state NMR.
28-33
 This work has revealed some of the details which 
underlie aggregate polymorphism and has begun to reveal distinctions between patient 
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phenotypes.
29
 Additionally, crystallographic studies of amyloidogenic peptide fragments have 
illuminated some of the chemical underpinnings of polymorphism and clarified fiber packing 
motifs.
34,39-41
 Recent advances in amyloid crystallography have also elucidated small, oligomeric 
structures formed by fragments of the A sequence.39,40,199-201 These intermediate aggregates, 
ranging from small trimers to higher order, pore-like aggregates, have revealed some 
commonalities in -strand formation by A which exist  in both these stabilized oligomers and 
the mature fibril, though their morphologies differ dramatically. While fibers remain the 
predominant subject for structural analysis, the recent paradigm shift within the amyloid 
community emphasizes the fundamental role of non-fibrillar intermediates as the predominant 
toxic species in AD.
19
 Thus, structural investigation of those intermediates has begun to take 
center stage, though the tools to fully characterize these intermediates formed by full length 
peptide remain in their relative infancy. 
 The propensity for A to aggregate in solution makes rapid acquisition of NMR data 
highly advantageous. 1D 
19
F NMR has been applied to monitor the aggregation propensity of 
various amyloidogenic peptides and distinguish their oligomeric intermediates.
174,202
 This 
method takes advantage of the minimal background afforded by the non-natural 
19
F atoms 
incorporated into a synthetic methionine derivative which improves the signal to noise ratio and 
shortens the time necessary to acquire each spectrum. However, due to the single site labeling, 
this method provides minimal structural insight, though it is an extremely valuable approach for 
investigating the general pathways of aggregation. A recent 2D 
1
H-
15
N correlation experiment, 
SOFAST-HMQC (band-Selective Optimized-Flip-Angle Short-Transient Heteronuclear Multiple 
Quantum Coherence), provides residue specific resolution in a matter of minutes while 
conventional HMQC experiments can require multiple hours for to acquire a single, well 
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resolved spectrum.
203
 This allows for the monomeric peptide to be monitored as a function of 
time while also making it possible to monitor the interaction of the peptide with a variety of 
ligands and protein binding partners.
163,204
 Relaxation and exchange based solution NMR 
experiments also allow us to characterize the interaction of monomeric peptide with larger 
structures (such as lipid bilayers or amyloid fibrils).
205-209
 Despite these methodologies, it 
remains difficult to characterize the intermediate aggregates of A in the absence of chemical 
modifications due to both the large size of the species and the inherent heterogeneity.
76,210,211
 The 
largest hurdle to the further characterization of intermediate aggregates is the validation of non-
disruptive preparation methods which can reproducibly generate stable and more homogeneous 
oligomeric species. 
 Solid-state NMR, while commonly applied to the study of fibrillar aggregates, is also 
capable of probing structural details of intermediate oligomers through a combination of careful 
sample preparation and selective labeling. Kotler et al. have recently applied radio frequency 
driven dipolar recoupling (RFDR) based 
1
H-
1
H experiments to investigate a stabilized, 
unstructured, off pathway oligomer of A40. The method took advantage of the abundance of 
protons inherent in the peptide and selective filtering of NMR signals using magic angle spinning 
(MAS) to only investigate structural parameters of a moderately sized aggregate. While the 
isolated aggregate was found to be relatively unstructured, the method is a viable approach for 
the future study of other intermediates. Solid-state NMR has also proved useful in exploring the 
mechanisms of A aggregation on lipid bilayers. By mixing selectively 13C labeled A40 with 
zwitterionic liposomes, it was possible to monitor different stages of peptide insertion into the 
lipid bilayer and subsequent membrane perturbation with atomic level resolution.
212
 A follow up 
study allowed for the observation of distinct aggregation pathways that are dependent upon both 
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peptide concentration and preexisting aggregate species.
43
 While not as developed as the solid-
state methods applied for the study of fibrillar aggregates, solid-state NMR has already proven 
itself invaluable in the investigation of amyloid intermediates and will continue to be a vital tool 
as the field explores new chemical and biological means by which aggregation intermediates 
may be stabilized. 
1.5. Dissertation objectives 
 While many studies have examined individual aspects of AD pathology in in vitro 
settings, there remains a substantial gap in our understanding of how various contributors to 
cytotoxicity, including A aggregation, metal dyshomeostasis, oxidative stress, and membrane 
disruption, are interrelated.
4,9,86
 The objectives of this thesis are to explore connections which 
bridge these individual facets of the disease and explore their relationships to one another. I first 
explore a new set of natural products (Phlorizin, Verbascoside, and Rutin) and their 
synthetically esterified derivatives (F2, VPP, and R2) for their ability to modulate metal-
associated A aggregation (Chapter 2). While natural products have been previously examined 
for their ability to modulate metalA aggregation, little work has explored how natural product 
frameworks may be synthetically modified to tune their reactivity.
195,204,213,214
 Then, in order to 
explore the effects of oxidative stress on membrane-mediated amyloid formation by A, I 
examine the effect of lipid bilayer thinning on the structure of monomeric A upon interaction 
with a synthetic membrane (Chapter 3) that the effect which thin  bilayers have upon the 
progression of A40 from its monomeric state to a fibrillar aggregate (Chapter 4). It has been 
documented that, as a result of the increased oxidative stress in the AD brain, polyunsaturated 
lipid molecules may be truncated due to peroxidation. These shortened lipids can subsequently 
incorporate into the neuronal bilayer and alter the chemical and mechanical properties of the 
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membrane with which A interacts and aggregates.50,51,215-218 Despite the pathological link 
between bilayer thinning, A aggregation, and AD, the role of pathologically thinned bilayers 
has yet to be investigated in protein aggregation. 
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Chapter 2 
Reactivity of Metal-Free and Metal-Associated Amyloid- with Glycosylated 
Polyphenols and Their Esterified Derivatives 
This chapter was adapted from the following publication: 
 Korshavn, K. J., Jang, M., Kwak, Y. J., Kochi, A., Vertuani, S., Manfredini, S., 
 Ramamoorthy, A. & Lim, M. H. Reactivity of Reactivity of Metal-Free and Metal-
 Associated Amyloid- with Glycosylated Polyphenols and Their Esterified Derivatives. 
 Sci. Rep. 5, 17842 (2015). 
2.1. Introduction 
 Alzheimer’s disease (AD) is a growing concern for global public health, spurred on, in 
part, by a lack of effective treatments or cures.
1
 While potential therapeutics have been 
developed for AD, their clinical success has been hindered by a limited molecular level 
understanding of the disease’s etiology.2-4 AD is commonly considered a protein misfolding 
disease characterized by the presence of proteinaceous aggregates, including senile plaques 
composed primarily of amyloid- (two main A forms, A40 and A42).
4-6
 A undergoes a 
progressive aggregation process, advancing from a small, intrinsically disordered peptide to 
intermediate oligomers of various sizes and structures, finally forming extended fibers; 
individual aggregates are believed to have varying degrees of toxicity and relevance in AD.
4,6,7
  
 The senile plaques in the AD-affected brain have been shown to contain elevated 
concentrations of transition metals, specifically Cu, Zn, and Fe, which suggests that these metal 
ions interact with and alter the aggregation of A.
4,8-10
 Understanding the interactions between 
metal ions and A in vitro could help elucidate potentially toxic mechanisms of both factors in 
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AD.
10-12
 These metal ions could accelerate the aggregation of A while simultaneously 
generating a variety of aggregates which may have biological functions distinct from those 
formed in the absence of metals.
9,10
 Additionally, the binding of A to redox active metals such 
as Cu and Fe can facilitate redox cycling and lead to the production of reactive oxygen species 
(ROS) resulting in an environment of exacerbated oxidative stress, a known characteristic of the 
AD-afflicted brain.
12-14
 The effects of these interactions in vivo remain unclear, however; in-
depth understanding is hindered by the multifactorial nature of the disease which makes it 
difficult to identify and quantify the influence of any of the potentially causative agents. 
 The application of chemical probes which can modulate the various factors associated 
with AD (e.g., A metal ions) may advance our understanding of the disease and uncover 
different toxic factors by isolating individual potential culprits. Unfortunately, there remains a 
lack of understanding about the relationship between small molecules and their subsequent 
biological functions with regards to the multiple aspects associated with AD. It is believed that 
hydrophobic interactions drive early stages of A aggregation and that compounds with similarly 
hydrophobic regions may effectively disrupt these aggregation-promoting forces and act as 
modulators of amyloid formation; some compounds of this nature have been investigated 
previously.
6
 It is unclear, though, which chemical moieties on these compounds may be the most 
potent at redirecting this process. To increase the specificity of anti-amyloidogenic compounds, 
multifunctional compounds have been designed to target and modulate additional aspects 
associated with AD (i.e., metal-associated A (metal–A), ROS) along with metal-free 
Asimultaneously.15-17 Compounds known to interact with A have been appended with known 
metal binding moieties to generate molecules capable of targeting both metal-free A and metal–
A, and these multifunctional compounds have demonstrated an ability to modulate both factors 
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to differing extents.
15,16
 As was the case with A interaction, however, rational design of these  
 
Figure 2.1. Chemical structures of glycosylated polyphenols and their derivatives. Phlorizin, 1-
(2,4-dihydroxy-6-(((2S,3R,4R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran -2-
yl)oxy)phenyl)-3-(4-hydroxyphenyl)propan-1-one; Verbascoside, (2R,3R,4R,5R,6R)-6-(3,4-
dihydroxyphenethoxy)-5-hydroxy-2-(hydroxymethyl)-4-(((2S,3R,4R,5R)-3,4,5-trihydroxy-6-
methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-3-yl (E)-3-(3,4-dihydroxy 
phenyl)acrylate; Rutin, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(((2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-((((2S,3R,4R,5S)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)methyl)tetra 
hydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; F2, (2S,3R,4R,6R)-2-(3,5-dihydroxy-2-(3-(4-
hydroxyphenyl)propanoyl)phenoxy)-6-((propionyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl 
tripropionate; VPP, (2S,3R,4R,5S)-2-(((2R,3R,4S,5R,6R)-2-(3,4-dihydroxyphenethoxy)-5-(((E)-
3-(3,4-dihydroxyphenyl)acryloyl)oxy)-3-(propionyloxy)-6-((propionyloxy)methyl)tetrahydro-
2H-pyran-4-yl)oxy)-6-methyltetrahydro-2H-pyran-3,4,5-triyl  tripropionate;  R2 , 
(2R,3R,4R,5S,6S)-2-(((2R,3R,4S,5R,6S)-6-((2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-
chromen-3-yl)oxy)-3,4,5-tris(propionyloxy)tetrahydro-2H-pyran-2-yl)methoxy)-6-methyl  
tetrahydro-2H-pyran-3,4,5-triyl tripropionate. 
 51 
 
metal binding moieties is hindered by a limited understanding of how these chelating agents 
function in the complex AD environment. Additionally, while it is desirable for compounds to 
also mediate oxidative stress, both through the modulation of ROS and free radicals, this 
function is similarly difficult to rationally incorporate into a structural entity. Efforts have 
previously been made to design multifunctional compounds for investigating the role of metal-
free A metalA, and pro-oxidants in AD,18 but the advancements in the field are generally 
slowed by limited information on the structure-function relationships between small molecules 
and their ability to regulate these disease related features. 
In order to gain better insight to this complex disease and to broaden current understanding 
of the connection between chemical structure and its function in the presence of factors 
associated with AD, three naturally occurring polyphenolic glycosides (Phlorizin, 
Verbascoside, and Rutin; Fig. 2.1) were chosen for a selective reactivity study towards both 
metal-free A and metalA. The investigation of naturally occurring compounds gives the 
substantial advantage of a minimal toxicity profile and a significant amount of background 
information from traditional medicine. Natural polyphenolic products have been previously 
shown to possess potential anti-amyloidogenic activity.
19,20
 Both Verbascoside and Rutin have 
demonstrated the capacity to redirect metal-free A aggregation towards nontoxic species,21-24 
and phloretin, the non-glycosidic version of Phlorizin, has exhibited an ability to prevent 
membrane-associated aggregation of A.25 While these preliminary studies examined 
aggregation in the absence of metal ions, the presence of known metal interaction moieties, 
phenol and catechol groups in Phlorizin and Verbascoside/Rutin, respectively, suggests that 
these compounds may be capable of simultaneously interacting with both A and metal ions.26-29 
Furthermore, all three compounds are known antioxidants, indicating that they could also help 
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mitigate oxidative stress associated with the AD-affected brain.
30-32
 Finally, these compounds are 
naturally glycosylated, a modification which has been proposed to improve bioavailability and 
distribution in the brain,
33-35
 as well as redirect the folding of metal-free A species.36,37 
Combined, these structural and chemical features suggest that Phlorizin, Verbascoside, and 
Rutin possess unique chemical features desirable for a probe to target multiple factors (i.e., 
metal-free and metal-bound A) and mitigate their toxicity leading to AD. 
To provide further insight into structure-activity relationships, selectively esterified 
derivatives, F2, VPP, and R2 (Fig. 2.1), were prepared and investigated alongside their parent 
compounds.
30-32
 Esterification could provide multiple benefits in the quest for an effective 
multifunctional probe while also acting as a general proof of concept that a prodrug approach is a 
viable method in the search for molecular tools in AD research. Ester formation may improve 
trafficking across lipid bilayers and facilitate targeted delivery of unprotected compounds within 
cells following cleavage by esterases; for these reasons, it is a commonly used modification in 
prodrug design.
38
 The ester groups may also improve the ability of the compounds to passively 
diffuse across the blood brain barrier (BBB) due to greater lipophilicity.
16,39
 Finally, the 
increased hydrophobicity could promote interactions between the compounds and the more 
aggregation prone regions of the A sequence, which are similarly hydrophobic.4,40 Overall, we 
believe that esterification may tune the ability of these three compounds to interact with both 
metal-free A and metal–A species while simultaneously improving the bioavailability, making 
them more suitable for future in vivo applications than their non-esterified counterparts. Using 
these six compounds, we aim to further expand the understanding of structure-function 
relationships between multifunctional probes towards both metal-free Aand metalA through 
a detailed, molecular level characterization. 
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2.2. Results 
2.2.1. Influence of polyphenols on metal-free and metal-induced aggregation in vitro 
 To initially investigate the effects of the six polyphenols (Fig. 21) on the structure and 
formation of both metal-free and metal–A aggregation pathways disaggregation (Fig. 2.2, 2.3, 
and A.1) and inhibition (Fig. A.2) experiments were performed. Both the more prevalent A40 
and the more aggregation-prone A42 isoforms were employed in both inhibition and 
disaggregation studies.
4
 For disaggregation experiments, A was allowed to aggregate in either 
the absence or presence of either CuCl2 or ZnCl2 for 24 h to form aggregated species. The 
compounds were then added to these aggregates and incubated for either 4 or 24 h to determine 
their ability to redirect the size and structure of pre-aggregated A species. In inhibition 
experiments, A (for metalA samples, A samples were treated with CuCl2 or ZnCl2) and the 
compounds were incubated for either 4 or 24 h to identify how they are capable of modulating 
the early steps in aggregation of both metal-free A and metalA. Gel electrophoresis with 
Western blot (gel/Western blot) using an anti-A antibody (6E10) and TEM were utilized to 
visualize the size distribution and morphology, respectively, of the resultant A species upon 
treatment with polyphenols in the absence and presence of metal ions for both disaggregation 
and inhibition experiments.
18,41
  
 Neither Phlorizin nor F2 demonstrated a significant ability to interact with A or metal–
A species in either a disaggregatory or inhibitory manner. In disaggregation experiments, 
gel/Western blot revealed that neither of these compounds was able to transform preformed A 
aggregates regardless of A isoform or metal presence (Fig. 2.2a and 2.3a, lanes 2 and 3). 
Phlorizin did appear to slightly change the morphology of species to marginally more disordered 
than untreated fibrils based on TEM results; however, large and extended A aggregates were  
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Figure 2.2. Modulation of preformed, metal-free and metal-induced A40 aggregates by 
Phlorizin, F2, Verbascoside, VPP, Rutin, or R2. A scheme of sample preparation for 
disaggregation experiments with A40 (top). (a) Analysis of the resultant A40 species by gel 
electrophoresis using Western blotting with an anti-A antibody (6E10). (b) TEM images of the 
morphologies of the resultant A species from the samples that were incubated for 24 h. 
Experimental conditions: [A40] = 25 M; [CuCl2 or ZnCl2] = 25 M; [compound] = 50 M; 4 
or 24 h incubation; pH 6.6 (for Cu(II) samples) or pH 7.4 (for metal-free and Zn(II) samples); 37 
°C; constant agitation. 
observed with and without metal ions (Fig. A.1). A similar lack of reactivity was observed in 
inhibition experiments (Fig. A.2, lanes 2 and 3). These two compounds appear unable to 
influence A40 and A42 aggregation behaviors regardless of the presence or absence of metal 
ions.  
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 Both Rutin and R2 showed mild reactivity with A and/or metal–A. Under 
disaggregation conditions, R2 produced low MW aggregates of A40 (< 15 kDa) after 4 h in the 
absence of metal ions; after 24 h in the absence of metal ions, both Rutin and R2 triggered 
relatively low MW aggregates (< 35 kDa) (Fig. 2.2a, lanes 6 and 7). The morphology of these 
species was slightly more compact that that of untreated A40 aggregates (Fig. A.1). A similarly 
sized range of A40 aggregates was generated by both Rutin and R2 when CuCl2 was present, 
after 24 h (Fig. 2.2a), and their morphology was even more compact than in the absence of metal 
ions (Fig. A.1). Neither Rutin nor R2 appeared to have any impact on preformed Zn(II)A40 
aggregates. The two compounds displayed a minimal or no effect upon preformed A42 
aggregates, regardless of the presence or absence of metal ions (Fig. 2.3a, lanes 6 and 7). Rutin 
and R2 presented a modest ability to redirect Cu(II)-induced aggregation of A40 or A42 after 
24 h incubation in inhibition studies (Fig. A.2, lanes 6 and 7). This suggests that both compounds 
have mild reactivity towards preformed A aggregates, favoring those formed in the presence of 
CuCl2. 
 Unlike the other four compounds, both Verbascoside and VPP were able to control A40 
and A42 aggregation, though to different extents. When preformed, metal-free A40 aggregates 
were treated with VPP for 4 h, a wide MW range (10-260 kDa) of species was formed (Fig. 2.2a, 
lane 5). These species were still observed after 24 h incubation. Verbascoside, the non-esterified 
parent compound of VPP, did not indicate any reactivity against preformed metal-free A40 
aggregates. Both compounds did demonstrate an ability to disaggregate Cu(II)A40 aggregates, 
however (Fig. 2.2, lanes 4 and 5). After 4 h incubations the two compounds mainly generated 
low MW (< 35 kDa) aggregates, evident by gel/Western blot. Following 24 h incubation, both 
compounds were capable of producing much wider MW ranges of Cu(II)A40 species (Fig. 
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2.2a, lanes 4 and 5). In the case of Zn(II)-containing aggregates; the initial disaggregation by 
Verbascosde and VPP was slower still. The A40 sample treated with Verbascoside for 24 h 
exhibited smaller-sized species while VPP triggered a wider range of aggregates, similar to that 
observed in both the absence of metals and the presence of Cu(II) (Fig. 2.2a). For all aggregates,  
 
Figure 2.3. Influence of Phlorizin, F2, Verbascoside, VPP, Rutin, or R2 on pre-generated 
metal-free and metal-induced A42 aggregates. A scheme of sample preparation for 
disaggregation experiments with A42 (top). (a) Analysis of the resultant A42species by gel 
electrophoresis using Western blot with an anti-A antibody (6E10). (b) TEM images of the 
morphologies of the resultant A species from the samples that were incubated for 24 h. 
Experimental conditions: [A42] = 25 M; [CuCl2 or ZnCl2] = 25 M; [compound] = 50 M; 4 
or 24 h incubation; pH 6.6 (for Cu(II) samples) or pH 7.4 (for metal-free and Zn(II) samples); 37 
°C; constant agitation. 
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both Verbascoside and VPP were able to convert large extended fibrils into smaller, generally 
amorphous structures (Fig. 2.2b). This same reactivity trend was observed when Verbascoside 
and VPP were added to metal-free and metal-associated, preformed A42 aggregates (Fig. 2.3). 
These compounds were capable of slightly altering A42 aggregates in the absence of metal ions. 
Additionally, VPP generated various-sized aggregates of Zn(II)A42 after 4 h only, a process 
which required 24 h with A40 (Fig. 2.3a). Similar to A40, unstructured A42 aggregates induced 
by treatment with the two compounds were shown by TEM (Fig. 2.3b).  
 Verbascoside and VPP also displayed reactivity towards A40 and A42 in inhibition 
experiments (Fig. A.2, lanes 4 and 5). Only VPP altered the aggregation of metal-free 
A40/A42, an effect which was evident after just 4 h with both isoforms. Both Verbascoside and 
VPP demonstrated inhibitory activity towards metalA40/A42. In the presence of Cu(II), the 
two compounds promoted a variety of aggregates to different extents after 4 h incubation; 
Verbascoside generated a smaller MW range of aggregates than VPP, suggesting that their 
activity may be size and/or conformation dependent. A similar trend in A aggregate size was 
observed in the presence of Zn(II) when Verbascoside and VPP were introduced (Fig. A.2). 
Verbascoside and VPP presented the similar time dependence in the presence of Zn(II) for the 
inhibition of A40 aggregation as they did with A40 disaggregation; their reactivity towards 
Zn(II)A40 was noticeable only after 24 h (Fig. A.2a). This suggests that the timescale of 
reactivity may be dependent upon solution conditions, specifically the presence or absence of 
metal ions in solution and the morphology of aggregates, at a given time. Taken together, the 
results from these disaggregation and inhibition experiments suggest that Verbascoside and 
VPP have a distinct capacity to modulate the aggregation of metal–A (as well as metal-free A 
in the case of VPP) which is generally absent for the other four compounds analyzed in this 
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study. It is interesting to observe that among the selected polyphenols the reactive Verbascoside 
and VPP both feature two catechol moieties, bearing the two characteristic ortho-hydroxy 
groups. Meanwhile, Rutin and R2 which only show mild reactivity have a single catechol 
moiety. Phloririzin and F2 have no catechol moieties while also presenting no noticeable 
reactivity with A species. This points to a potential role for the catechol moiety in the activity 
of these compounds. Additionally, from this set of compounds, it appears that structural 
modification of the sugar moiety (i.e., selective esterification) can drastically alter the function of 
the parent compound, as was seen for both Verbascoside/VPP and Rutin/R2. 
2.2.2. Metal binding properties of polyphenols 
 In order to elucidate the molecular level interactions responsible for the varied anti-
amyloidogenic activity of the polyphenols towards metal–A species it is necessary to 
understand the potential binding of each compound with the component parts of system: metal 
ions and A monomers/aggregates. The potential interaction between the polyphenols and metal 
ions was investigated first. The OH groups found on the aromatic rings of all six compounds 
could potentially interact with transition metals; the catechol moieties of Verbascoside, VPP, 
Rutin, and R2 are especially likely to bind metal ions in a manner similar to previously reported 
polyphenols.
20,28,42-44
 It has already been suggested that both Verbascoside and Rutin could 
interact with Cu(II) in solution.
45-47
 The Cu(II) binding properties of Phlorizin/F2, 
Verbascoside/VPP, and Rutin/R2 were examined by UVVis while the Zn(II) binding of 
Verbascoside and VPP was monitored by 
1
H NMR due to a lack of significant optical changes 
in the spectra when the ligand was treated with Zn(II) (Fig. 2.4, A.3, and A.4).  
The UVVis spectra of the six polyphenols showed different levels of spectral changes 
following the titration of CuCl2 in buffered aqueous solution (pH 7.4; Fig. 2.4a and A.3). 
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Addition of CuCl2 to both Verbascoside and VPP in solution induced a slight change in the 
absorption bands at ca. 330 nm and 405 nm, implying potential interaction between the catechol 
moieties of both ligands and Cu(II) in solution  (Fig. 2.4a).
48
 The spectral change is more drastic 
in VPP than in Verbascoside, which suggests that esterification of the OH groups in the sugar 
ring could reduce their competitive interaction with Cu(II) and promote binding by the catechol 
moieties. Neither compound presented significantly noticeable spectral shifts indicative of  
 
 
Figure 2.4. Metal binding studies of Verbascoside and VPP. (a) Cu(II) binding studies of 
Verbascoside (Verb) and VPP by UVVis. Samples were incubated for 2 h with or without 
Cu(II) (0.5 - 10 equiv) at pH 7.4 at room temperature. (b) Zn(II) binding studies of Verbascoside 
(top) and VPP (bottom) by 
1
H NMR. The samples of compounds (2 mM) were titrated with 
ZnCl2 (0, 2, and 10 equiv) in DMSO-d6 at room temperature. 
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complex formation, however, suggesting that interaction of either Verbascoside or VPP with 
Cu(II) in solution could be weak. Previous studies on complex formation between Verbascoside 
and Cu(II) are unclear about the strength of the interaction which indicates that complexation 
could depend upon experimental conditions (i.e., buffer, salt concentration, pH).
45,49
 Addition of 
CuCl2 to solutions of either Phlorizin or F2 induced no significant shift in spectral features, 
likely due to the minimal interaction of the phenol moiety in the compounds for Cu(II) in 
solution (Fig. A.3). The presence of Cu(II) did induce modest changes in the spectrum of Rutin, 
including a decrease in the primary peak at ca. 330 nm and an increase in a shoulder at ca. 425 
nm (Fig. A.3). This may be caused by the interaction between the catechol moiety and Cu(II). 
These shifts are similar, though of smaller magnitude, to those previously observed for 
RutinCu(II) complexes.50,51 Finally, R2 exhibited slight spectral changes over the course of the 
titration, suggesting minimal interaction with Cu(II) in solution (Fig. A.3), suggesting that 
esterification of Rutin could change the interaction between the ligand and Cu(II). These results 
suggest that only Verbascoside, VPP, and Rutin have an observable ability to interact with 
Cu(II) under the conditions of this study.  
The interaction of Verbascoside and VPP with Zn(II) was also investigated by 
1
H NMR in 
DMSO-d6 (Fig. 2.4b). When Zn(II)
 
was titrated into Verbascoside up to 2 equiv, all phenolic 
protons exhibited some sharpening, likely the result of weak association with the metal in 
solution and subsequent decrease in the exchange rate of bound protons with the solvent. When 
additional Zn(II) was added to solution, however, the resonances associated with the caffeic acid 
moiety began to broaden. The hydroxytyrosine phenolic protons showed minimal change upon 
addition of more Zn(II). Selective broadening suggests that Zn(II) preferentially associates with 
the caffeic acid catechol moiety. A similar pattern was observed when Zn(II) was added to VPP. 
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During the titration, only caffeic acid associated protons broadened, suggesting interaction with 
the metal and subsequent proton exchange with the solvent. No other proton resonances 
demonstrate any shifts or broadening over the course of the titration for either compound (Fig. 
A.4). This would suggest that in both Verbascoside and VPP, Zn(II) selectively interacts with 
the phenolic protons of the caffeic acid moiety over all other portions of the compounds. Overall, 
both Verbascoside and VPP are shown to interact with both Cu(II) and Zn(II) under the 
conditions employed in this study, suggesting that this may be partially responsible for the ability 
of  these compounds to redirect metalA aggregation (vide supra). 
2.2.3. Interaction of polyphenols with multiple A forms 
 Given the ability of both Verbascoside and VPP to redirect the morphology and 
aggregation of A, the direct interaction of the two compounds, along with both Phlorizin and 
R2, with monomeric A40 was investigated (Fig. 2.5 and A.5). 2D band-Selective Optimized-
Flip-Angle Short-Transient Heteronuclear Multiple Quantum Coherence (SOFAST-HMQC) 
NMR experiments were performed to identify potential residue-specific interactions between 
monomeric A peptide and the compounds.52 The chemical shift perturbation (CSP) for each 
resolvable residue was calculated by comparing the spectrum of ligand-free A40 with that of 
A40 in the presence of excess ligand (10 equiv) and these CSP values were compared to the 
average CSP values (Fig. 2.5a and b, and A.4) to identify potentially favored interactions.
20,28
 All 
four compounds induced some mild to moderate (0.020.035 ppm) chemical shifts in varying 
regions of the peptide. Verbascoside (Fig. 2.5c) triggered a distinct shift in D23 and also weakly 
perturbed Q15 while VPP (Fig. 2.5d) caused some shift in Y10, E11, Q15, and F20. The 
interactions of Verbascoside seem to favor both polar and charged residues that are centrally 
located in the sequence, suggesting that both hydrophilic interactions and hydrogen bonding 
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Figure 2.5. Ligand interaction with monomeric A40 by 2D 
1
H/
15
N SOFAST-HMQC NMR. 
Verbascoside (a) and VPP (b) were titrated into a solution of uniformly 
15
N-labeled A40 (80 
M in 20 mM PO4, 50 mM NaCl, pH 7.4, 7% D2O (v/v), 10 °C). Blue color represents the 
spectrum obtained upon addition of 10 equiv of the ligand to A40 (red color: the spectrum of 
A40 only). All spectra were aligned at G29 due to non-uniform broadening of the water peak as 
a reference. Chemical shift perturbation (CSP) between the 0 and 10 equiv of all resolved 
residues was calculated and plotted as a function of the amino acid residue number in A40 for 
(c) Verbascoside, (d) VPP, (e) Phlorizin, and (f) R2. All CSP values are compared to the 
average (dashed line) and average + standard deviation (dotted line) for each titration. Values 
which exceed the average + standard deviation line are considered to be significant, suggesting 
potential interaction. 
could direct potential ligand binding. VPP, however, perturbed a mixture of hydrophobic and 
hydrophilic residues, suggesting that the added acyl groups could encourage some nonpolar 
contacts during ligand interaction with A – stacking between VPP and the aromatic side 
chains of Y10 and/or F20 could also be responsible for the observed shifts. Despite causing shifts 
in unique residue resonances, both compounds alter residues near the purported metal binding 
site of A (residues 1-16) suggesting that the compounds preferentially interact with the N-
terminus and may be oriented in a manner which facilitates interaction with metal ions when 
present in solution or could alter the conformation of the N-terminus of the peptide, disrupting 
the peptide’s ability to bind metal ions.4,8-10 Phlorizin (Fig. 2.5e) caused minor chemical shifts in 
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both the hydrophobic core (F19-A21) and the C-terminus (V36); nonpolar forces may be 
responsible for any prospective PhlorizinA40 interaction. Rutin (Fig. 2.5f) prompted small 
shifts in regions similar to those altered by Phlorizin (L17 and M35). These small and non-
localized chemical shifts could be indicative of weak interaction and/or non-specific binding to 
the peptide by the two compounds. Both Phlorizin and R2, which show limited or no influence 
on amyloidogenesis, display potentially weak interactions with more C-terminal residues while 
the interaction of both Verbascoside and VPP with A appear to be more centrally or N-
terminally located. Due to the modest CSP values observed, these data may suggest a general 
preference for interaction rather than a conventional, structured binding site for all compounds 
examined. Our NMR studies, therefore, suggest a possible molecular mechanism responsible for 
their differing activities towards A species in vitro (vide supra). Ligand association with the N-
terminus (close to the metal binding site in A) may be favorable in the development of 
multifunctional compounds to target metal-free and/or metal-associated A species while 
interacting with the central hydrophobic residues of A may also allow for general inhibition, as 
has been previously predicted.
4,6,9,10,15
 
To gain further molecular level insight into the interactions between these polyphenols and 
different A structures, saturation transfer difference (STD) NMR was employed to map the 
regions of both Verbascoside and VPP which bind to preformed A42 fibrils (Fig. 2.6).
18,28,53,54
 
The intensity of peaks within the STD spectra, relative to the reference spectra, is associated with 
the proximity of the ligand’s protons to the fibril.54 From these values, a group epitope map can 
be generated, determining which protons of Verbascoside and VPP are in proximity to and 
binding with the fibrils. Verbascoside (Fig. 2.6c) only showed STD signals for protons linked to 
the glucose and rhamose rings. While most of these protons presented modest to weak signals in 
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the STD spectrum, the protons on the C6 of the glucose ring indicated an extremely strong STD 
effect. For VPP, weak STD effect was observed around all methyl and ethyl protons of the esters 
appended to the sugar moieties. The stronger STD effect was observed around both the caffeic 
acid and hydroxytyrosol moieties, localized especially around the two aromatic protons of the 
catechol groups (Fig. 2.6d). This suggests that the esterification of the sugar rings of 
Verbascoside blocks the binding of the compound to the fibrils through the two sugar rings, 
redirecting their interaction to a different portion of the compound. It may be that the multiple 
hydroxyl groups of the sugars promote hydrogen bonds with some of the exposed side chains of 
the fibril; the esterification of the sugar rings could make these interactions sterically unfavorable 
and direct VPP to interact through hydrogen bonds and –interactions through the catechol 
moieties of the compound instead.  
 The different binding modes identified by STD experiments led us to explore the affinity 
of these two compounds for fibrillar A. Using a fluorescence blue shift assay, the change in the 
fluorescence emission wavelength was monitored as fibril was titrated into solution (Fig. A.6a 
and b).  Verbascoside and VPP were shown to have an affinity of 7.80 ± 0.75 M and 6.98 ± 
0.80 M, respectively, under the condition employed in this study. Despite very different modes 
of binding to the fibril, the compounds have nearly identical affinities. It should be noted that the 
actual affinity for the fibril in solution is likely stronger than those measured; the concentration 
of fibrils was calculated based on the monomer equivalent concentration. It is not possible to 
measure the molar concentration of fibrils in solution given their heterogeneous length and 
subsequently heterogeneous molecular weight. The fibril concentration is likely much lower than 
the monomer equivalent which would affect the concentration values used in the fit. Because the 
exact fiber concentration cannot be measured, however, and because the same sample of fibril 
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was used for both titrations, we are confident that these results are internally consistent and 
suggest that the two compounds have very similar affinities. 
 
Figure 2.6. Ligand Interaction with fibrillar A42 by saturation transfer difference (STD) NMR. 
STD NMR spectra of (a) Verbascoside and (b) VPP at a 250:1 ligand to peptide ratio using pre-
assembled A42 fibrils (1 M). Comparison of the STD signal intensity (red) to the STD 
reference intensity (black) reflects the relative proximity of the corresponding proton to the A42 
fibril. The STD effect calculated from relative intensities was correlated to the structure of 
Verbascoside (c) and VPP (d) to generate group epitope maps. 
The distinct difference in group epitope but similar affinity led us to investigate the binding 
site on the fibril for these two compounds; it was expected that two compounds with similar 
affinities but unique binding moieties would likely bind to separate regions of the fibril structure 
and therefore not compete for binding. To probe this, we performed a competition titration 
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experiment in which fibrils were first treated with 1 equiv of a compound (either Verbascoside 
or VPP) and then titrated with the other compound. The intensity of an STD peak associated 
with each compound (relative to the intensity of the same peak in the reference spectrum) was 
then used to monitor the binding of each compound to the fibril. As the competing compound is 
titrated into solution, if the compounds bind in the same site, it is expected that the relative 
intensity of the first compound’s peak will gradually decrease while the relative intensity of the 
titrant’s peak will increase as it competes the first compound off of the binding site. Conversely, 
under non-competitive binding conditions, the initial compound would maintain a constant 
relative intensity while the relative intensity of the titrant would increase as it binds at higher and 
higher concentrations. When Verbascoside was titrated into a solution already containing VPP 
and fibrils (Fig. A.6c), it was observed that the relative intensity of the peak associated with 
Verbascoside increased during the titration while the relative intensity of the peak associated 
with VPP gradually decreased. This suggests that Verbascoside competes with VPP for a 
similar binding site on the fibril. The reverse of this experiment was performed (VPP titrated 
into a solution already containing Verbascoside and fibrils; Fig. A.6d) and the same trend was 
observed. The relative intensity of the VPP peak increased while the relative intensity of the 
Verbascoside peak decreased slightly. This implies that, while the two compounds bind to the 
fibril using unique portions of their related structure, they are targeting a similar location on the 
fibril. Additionally, the blue shift assay suggests that they do so with a nearly identical affinity. 
This is unexpected and suggests that the esterification changes how the two compounds are able 
to disaggregate fibrillar species (vide supra) but they bind to the fibril in a relatively similar 
manner though using unique parts of their structure. It could be that the differing orientation of 
the sugar and catechol moieties of the two compounds is at least partly responsible for this 
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difference in reactivity as STD group epitope maps reveal that the orientation is unique between 
compounds. 
2.2.4. Antioxidant properties 
 Because oxidative stress is believed to play a role in AD, it would be valuable for 
multifunctional probes to possess antioxidant activity, on top of the ability to interact 
simultaneously with A species and various transition metal ions.9,13,14 The ability of these six 
compounds to scavenge an organic radical cation (i.e., ABTS
•+
) was determined by the Trolox 
equivalence antioxidant capacity (TEAC) assay using cell lysates (Fig. 2.7a).
55,56
 Both 
Verbascoside and Rutin, two known antioxidants,
31,32,57
 scavenged ABTS
•+
 slightly better than 
Trolox (by a factor of ca. 1.4 and 1.2, respectively). VPP, Phlorizin, and F2 showed a lower 
ability to scavenge ABTS
•+
 relative to Trolox, suggesting limited function as antioxidants 
relative to the other compounds investigated herein. R2 presented no ability to scavenge ABTS
•+
. 
This, again, indicates that esterification of the sugar moiety transforms the function of the 
polyphenols. In this case, the antioxidant capacity of the all compounds was reduced upon 
esterification. Verbascoside’s activity was reduced by ca. 65% while Rutin lost all activity. The 
activity of Phlorizin was reduced by ca. 40%. This reduction in antioxidant capacity is 
surprising given the conservation of the catechol structures between Verbascoside/VPP and 
Rutin/R2 which is thought to be potentially responsible for ABTS
•+
 quenching through semi-
quinone and quinone formation.
28,56
 
2.2.5. Regulating cytotoxicity related to metal-free and metal-associated A
 Previous studies of Verbascoside and Rutin have suggested the two compounds may 
alleviate the toxicity of A species in SH-SY5Y and APPswe cells, respectively.22,24 We probed 
this relationship further to examine the effect of these two compounds, as well as VPP, on the  
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Figure 2.7. Biological activities of Verbascoside (Verb), VPP, Rutin, R2, Phlorizin (Phlo), 
and F2. (a) Free-radical scavenging activity of Verbascoside, VPP, Rutin, R2, Phlorizin, and 
F2 evaluated by a cell lysate-based TEAC assay. The TEAC values are relative to a vitamin E 
analogue, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). (b) Influence of 
Verbascoside, VPP, and Rutin on cytotoxicity induced by metal-free A and metalA species 
in N2a cells. Cells treated with A40 or A42 (20 M), a metal chloride salt (CuCl2 or ZnCl2; 20 
M), and a compound [Verbascoside, VPP, and Rutin (20 M)] were incubated for 24 h at 37 
°C. Cell viability was determined by the MTT assay. Values of cell viability (%) were calculated 
compared to that of cells treated with DMSO only (0-1%, v/v). Error bars represent the standard 
errors from three independent experiments.  
cytotoxicity of both metal-free A and metal–A in murine Neuro-2a neuroblastoma (N2a) cells. 
In the absence of A, Verbascoside was relatively nontoxic with and without metal ions (Fig. 
A.7). VPP, however, reduced cell viability (ca. 70%) at high concentrations in the presence of 
either Cu(II) or Zn(II), but showed minimal toxicity in the absence of metal ions. Rutin had no 
significant impact on cell viability under any conditions (Fig. A.6). 
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or Zn(II), 20 M) indicated viability of ca. 7080% under all conditions (Fig. 2.7b). The 
addition of Verbascoside (20 M) improved cell survival (ca. 90100%) regardless of both A 
isoforms and the presence or absence of metal ions. VPP (20 M), however, was generally 
unable to regulate A-triggered cytotoxicity. Finally, treatment of cells with Rutin (20 M) 
yielded slight improvements in cell survival under all conditions. Overall, Verbascoside was 
capable of attenuating the broad toxicity indicated in the presence of both metal-free A and 
metalA. Furthermore, esterification of the compound is shown to limit these protective 
capabilities. 
2.3. Discussion 
 Naturally occurring polyphenolic glycosides (Phlorizin, Verbascoside, and Rutin), 
along with their esterified derivatives (F2, VPP, and R2), were investigated for their potential to 
modulate the aggregation and toxicity of metal-free A and metal–A. Both Verbascoside and 
VPP, bearing multiple catechol moieties, were capable of distinctly redirecting the aggregation 
of metal-free A (mainly, VPP) and/or metal–A to different extents, as confirmed by both 
biochemical and TEM studies. The ability of these two compounds to interact with both metal 
ions and A was confirmed through physical methods, including UV-Vis and 1D/2D/STD NMR. 
Verbascoside and VPP are able to interact with both Cu(II) and Zn(II) as well as with multiple 
forms of A. The esterification of Verbascoside to VPP distinctly alters the interactions 
between the compounds and the components of the metalA system studied herein, suggesting 
that the properties (metal binding and A interaction) can be tunable by synthetic modifications. 
In addition, Verbascoside is shown to have some promising chemical properties for a potential 
probe (antioxidant capacity, no toxicity, and cytoprotective against both metal-free A and 
metal-A). Overall, this study points to Verbascoside as a promising starting point for 
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constructing a new multifunctional probe to interrogate the etiology of AD.  
 This study also lends insight into the efficacy of unique chemical moieties in design of 
anti-amyloidogenic compounds. Comparing Phlorizin, Verbascoside, and Rutin to each other, 
there is a direct correlation between the number of catechol moieties and the efficacy of each 
compound against A and metalA aggregation. This is further supported by the group epitope 
map generated from STD NMR for VPP which shows strong STD effect around both catechols. 
This suggests that the catechol moiety specifically, not just polyphenols as a general class of 
compounds, may be effective at redirecting the protein misfolding. Previous studies have also 
indicated that including a catechol-like moiety makes a small molecule more effective
28
; two of 
the most thoroughly investigated anti-amyloidogenic natural products, EGCG and curcumin, 
contain multiple variations of the catechol moiety (pyrogallol for EGCG, o-methyl-catechol for 
curcumin), further indicating that the catechol moiety is an effective component of an anti-
amyloidogenic probe.
20,58
 It should be noted, however, that catechol-containing compounds have 
been shown to be promiscuous in their action and functionality so their use and functionalization 
must be carefully considered in compound design for in vivo applications in order to avoid off-
target effects.
59,60
  
 We have also highlighted the importance of carefully chosen synthetic alterations to 
efficacious reagents. In this suite of compounds, it is apparent that esterification of the sugar 
moieties affected the efficacy of the compounds in the various assays to differing extents; 
esterification increased the ability of VPP to alter the structure of metal-free A aggregates 
while simultaneously maintaining its affinity for preformed fibrils relative to that of 
Verbascoside, its parent compound. Esterification also reduced the ability of all compounds to 
scavenge organic radicals despite not directly modifying the catechol moiety thought to be 
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responsible for the scavenging activity. Overall, this points to the unpredictability inherent in 
small molecule design for complex biological systems; with many variables all contributing to 
the disease phenotype, it is challenging, if not impossible, to accurately predict the effects of 
small structural changes on a compounds efficacy against the suite of potential targets. Thus, the 
performance of the compounds evaluated here may serve as a benchmark for which compounds 
are most worthwhile investigating further in more complex and biologically relevant systems. 
Furthermore, it indicates the care which must be taken when functionalizing known compounds. 
Even potentially reversible changes, such as esterification, may drastically alter the compound’s 
function, in both beneficial and detrimental ways. Importantly, however, it appears from the data 
presented herein that Verbascoside possesses positive characteristics for a compound in the 
investigation of the role of A in AD and, furthermore, is structurally amenable to a variety of 
future derivatization aimed at further improving its function. 
2.4. Methods 
2.4.1. Materials and procedures 
 All reagents were purchased from commercial suppliers and used as received unless 
otherwise noted. The natural products (Phlorizin, Verbascoside, and Rutin) and their 
previously synthesized, esterified derivatives (F2, VPP, and R2) were prepared following the 
previously reported methods.
30-32
 A40 and A42 were purchased from Anaspec (Fremont, CA). 
Transmission electron microscopy (TEM) images were recorded on a Philips CM-100 
transmission electron microscope (Microscopy and Image Analysis Laboratory, University of 
Michigan, Ann Arbor, MI, USA). Optical spectra for metal binding were recorded on an Agilent 
8453 UV–Visible (UV–Vis) spectrophotometer. Nuclear magnetic resonance (NMR) spectra for 
the characterization of Zn(II) binding studies of Verbascoside and VPP were acquired on an 
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Agilent 400 MHz NMR spectrometer. NMR studies of 
15
N-labeled A40 with ligands were 
carried out on a Bruker 600 MHz NMR spectrometer equipped with a cryogenic probe. 
Absorbance values for biological assays, including the TEAC assay and cell viability assay, were 
measured on a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA, USA). 
2.4.2. Amyloid- (A) inhibition and disaggregation experiments 
 A experiments were performed according to previously published methods.28,41 Prior to 
the sample preparation, A40 or A42 was dissolved with ammonium hydroxide (NH4OH, 1% 
v/v, aq), aliquoted, lyophilized, and stored at -80 °C. Stock solutions (ca. 200 M) of A40 and 
A42 were prepared by dissolving the lyophilized peptide in 1% NH4OH (10 L) and diluting 
with doubly distilled (dd) H2O. The peptide stock solution was diluted to a final concentration of 
25 M in buffered solution containing HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid; 20 M, pH 6.6 for Cu(II) samples; pH 7.4 for metal-free and Zn(II) samples] and NaCl 
(150 M). For the inhibition studies,28,41 compound (50 M final concentration, 1% v/v DMSO) 
was added to the sample of A40 or A42 in the absence and presence of a metal chloride salt 
(CuCl2 or ZnCl2, 25 M) followed by incubation for 4 and 24 h at 37 °C with constant agitation. 
For the disaggregation studies,
28,41
 A40 or A42 with and without metal ions was first incubated 
for 24 h at 37 °C with continuous agitation prior to the addition of compound (50 M). The 
resulting samples were incubated for an additional 4 or 24 h at 37 °C with constant agitation. 
2.4.3. Gel electrophoresis with Western blotting 
 The samples from the inhibition and disaggregation experiments were analyzed by gel 
electrophoresis with Western blot using an anti-A antibody (6E10).20,28 Each sample (10 L) 
was separated on a 10-20% Tris-tricine gel (Invitrogen, Grand Island, NY, USA). Following 
separation, the gel was transferred onto nitrocellulose membrane which was blocked with bovine 
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serum albumin (BSA, 3% w/v, Sigma-Aldrich, St. Louis, MO, USA) in Tris-buffered saline 
(TBS) containing 0.1% Tween-20 (TBS-T) for 3 h at room temperature. The membrane was 
treated with antibody (6E10, Covance, Princeton, NJ, USA; 1:2000) in a solution of BSA (2% 
w/v) in TBS-T overnight at 4 °C. Following washing, the membrane was treated with 
horseradish peroxidase-conjugated goat antimouse secondary antibody (1:5000; Cayman 
Chemical, Ann Arbor, MI, USA) in 2% BSA in TBS-T solution for 1 h at room temperature. 
Protein bands were visualized using ThermoScientific Supersignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, Rockford, IL, USA). 
2.4.4. Transmission electron microscopy 
 The samples for TEM were prepared following a previously reported method.
28,41
  Glow-
discharged grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA, USA) 
were treated with the samples from the disaggregation experiments (5 L, 25 M A) for 2 min 
at room temperature. Excess sample was removed with filter paper and washed with ddH2O. 
Each grid was stained with uranyl acetate (1% w/v, ddH2O, 5 L, 1 min), blotted to remove 
excess stain, and dried for 15 min at room temperature. TEM images were taken by a Philips 
CM-100 transmission electron microscope (80 kV, 25,000x magnification). 
2.4.5. Metal binding studies 
 The interaction of Phlorizin, F2, Verbascoside, VPP, Rutin, and R2 with Cu(II) and 
Zn(II) was determined by UVVis or 1H NMR, respectively, based on previously reported 
procedures.
20,61
 A solution of ligand (20 M, pH 7.4) was prepared, treated with 0.5 to 10 equiv 
of CuCl2, and incubated at room temperature for 2 h (for Phlorizin, F2, Verbascoside, VPP, 
Rutin, and R2). The optical spectra of the resulting solutions were measured by UVVis. The 
interaction of both Verbascoside and VPP with ZnCl2 was observed by 
1
H NMR (500 MHz). 
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ZnCl2 was titrated into a solution of Verbascoside or VPP (2 mM) in DMSO-d6 and the spectra 
were recorded.  
2.4.6. 2D NMR spectroscopy 
 The interaction of A40 with Phlorizin, Verbascoside, VPP, and R2 was monitored by 
2D band-Selective Optimized Flip-Angle Short Transient Heteronuclear Multiple Quantum 
Coherence (SOFAST-HMQC) at 8 °C.
52
 Uniformly-
15
N-labeled A40 (rPeptide, Bogart, GA, 
USA) was first dissolved in 1% NH4OH and lyophilized. The peptide was re-dissolved in 3 L 
of DMSO-d6 (Cambridge Isotope, Tewksbury, MA, USA) and diluted with phosphate buffer, 
NaCl, D2O, and ddH2O to a final peptide concentration of 80 M (20 mM PO4, pH 7.4, 50 mM 
NaCl, 7% v/v D2O). Each spectrum was obtained using 64 complex t1 points and a 0.1 sec 
recycle delay on a Bruker Avance 600 MHz spectrometer. The 2D data were processed using 
TOPSPIN 2.1 (from Bruker). Resonance assignment was performed with SPARKY 3.1134 using 
published assignments for A40 as a guide.
62-64
 Chemical shift perturbation (CSP) was calculated 
using the following equation: 
∆δNH = √∆δH2 + (
∆δN
5
)
2
 
2.4.7. Saturation transfer difference (STD) NMR spectroscopy 
 For the STD NMR
53
 experiments, an 150 M solution of fibrillar A42 was prepared by 
incubating A42 for 24 h at 37 °C with constant agitation in 10 mM deuterated Tris–DCl, 95% 
D2O at pD 7.4 (corrected for the isotope effect). The samples for STD experiments were 
prepared by diluting fiber to 1 M (effective monomer concentration) into 10 mM deuterated 
Tris–DCl to which was added 250 M of ligand (0.5% DMSO-d6). STD experiments were 
acquired with a train of 50 dB Gausian-shaped pulses of 0.049 sec with an interval of 0.001 sec 
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at either -1.0 ppm (on resonance) or 40 ppm (off resonance) with a total saturation time of 2 sec 
on a Bruker 600 MHz NMR spectrometer. A total of 1024 scans were recorded for the STD 
spectrum and 512 scans were recorded for the reference spectrum at 25 °C. An inter-scan delay 
of 1 sec was used for both the STD and the reference experiments.  
For the competition experiments with Verbascoside and VPP, the above procedure was 
followed for sample preparation. STD experiments were acquired with a train of 50 dB Gausian-
shaped pulses of 0.049 sec with an interval of 0.001 sec at either -1.0 ppm (on resonance) or 40 
ppm (off resonance) with a total saturation time of 2 sec on a Bruker 500 MHz NMR 
spectrometer. A total of 2048 scans were recorded for the STD spectrum and 1024 scans were 
recorded for the reference spectrum at 25 °C. An inter-scan delay of 1 sec was used for both the 
STD and the reference experiments. To a solution already containing either Verbascoside or 
VPP (250 M), the other compound was titrated to 0.5 equiv (125 M), 1 equiv (250 M), and 3 
equiv (750 M). The intensity of peaks unique to Verbascoside (3.85 ppm) and VPP (7.78 ppm) 
in the STD spectra relative to their intensity in the reference spectra were used to monitor the 
binding of the compounds to the fiber. 
2.4.8. Blue shift fluorescence assay 
 The change in the fluorescence emission wavelength of Verbascoside or VPP was 
monitored upon treatment with A42 fibrils on a Fluoromax-4 Spectrofluorimeter (Horiba 
Scientific, Edison, NJ, USA). A 25 M solution of either Verbascoside or VPP in buffer (20 
mM PO4, pH 7.4, 50 mM NaCl) was titrated with preformed A42 fibrils, prepared as described 
above for STD experiments. The fluorescence emission was monitored between 380 and 550 nm 
following excitation (350 nm for Verbascoside and 330 nm for VPP) with slits set for 5 nm 
bandwidths. The blue shift was calculated by the difference between the emission maximum 
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wavelength of the titration point and the emission maximum wavelength of the compound in 
absence of fibrils. The data was then fit to a hyperbolic curve to calculate the Kd value. 
2.4.9. Trolox equivalent antioxidant capacity (TEAC) assay 
 The antioxidant activity of Phlorizin, F2, Verbascoside, VPP, Rutin, and R2 was 
determined by the TEAC assay employing cell lysate following the protocol of the antioxidant 
assay kit purchased from Cayman Chemical Company (Ann Arbor, MI, USA) with 
modifications.
18
 Murine Neuro-2a (N2a) cells were used for this assay. This cell line, purchased 
from the American Type Culture Collection (ATCC, Manassas, VA, USA), was maintained in 
media containing 50% Dulbecco’s modified Eagle’s medium (DMEM) and 50% OPTI-MEM 
(GIBCO), supplemented with 10% fetal bovine serum (FBS, Sigma), 1% Non-essential Amino 
Acids (NEAA, GIBCO), 2 mM glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin 
(GIBCO). The cells were grown and maintained at 37 °C in a humidified atmosphere with 5% 
CO2. For the antioxidant assay using cell lysates, cells were seeded in a 6 well plate and grown to 
approximately 80-90% confluence. Cell lysates were prepared following the previously reported 
method with modifications.
65
 N2a cells were washed once with cold PBS (pH 7.4, GIBCO) and 
harvested by gently pipetting off adherent cells with cold PBS. The cell pellet was generated by 
centrifugation (2,000 x g for 10 min at 4 °C). This cell pellet was sonicated on ice (5 sec pulses, 
5 times with 20 sec intervals between each pulse) in 2 mL of cold Assay Buffer (5 mM 
potassium phosphate, pH 7.4, containing 0.9% NaCl and 0.1% glucose). The cell lysates were 
centrifuged at 5,000 x g for 10 min at 4 °C. The supernatant was removed and stored on ice until 
use. To standard and sample wells in a 96 well plate, cell lysates (10 L) were delivered; they 
were followed by addition of compound, metmyoglobin, ABTS, and H2O2 in order. After 5 min 
incubation at room temperature on a shaker, absorbance values at 750 nm were recorded. The 
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final concentrations (0.045, 0.090, 0.135, 0.180, 0.225, and 0.330 mM) of Trolox (Sigma-
Aldrich; Trolox = 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; dissolved in 
DMSO) and all polyphenolic glycosides were used. The percent inhibition was calculated 
according to the measured absorbance [% Inhibition = (A0A)/A0, where A0 is absorbance of the 
supernatant of cell lysates] and was plotted as a function of compound concentration. The TEAC 
value of ligands was calculated as a ratio of the slope of the standard curve of the compound to 
that of Trolox. 
2.4.10. Cell viability measurements 
 Cell viability upon treatment with compounds was determined using the MTT assay 
(Sigma). N2a cells were seeded in a 96 well plate (15,000 cells in 100 L per well). The cells 
were treated with A (20 M) with or without either CuCl2 or ZnCl2 (20 M), followed by the 
addition of compound (20 M, 1% v/v final DMSO concentration for Verbascoside, VPP, and 
Rutin) and incubated for 24 h in the cells. After incubation, 25 L MTT [5 mg/mL in phosphate 
buffered saline (PBS), pH 7.4, GIBCO, Grand Island, NY, USA] was added to each well and the 
plate was incubated for 4 h at 37 °C. Formazan produced by the cells was solubilized using an 
acidic solution of N,N-dimethylformamide (DMF, 50% v/v, aq) and sodium dodecyl sulfate 
(SDS, 20% w/v) overnight at room temperature in the dark. The absorbance was measured at 600 
nm using a microplate reader. Cell viability was calculated relative to cells treated an equivalent 
volume of DMSO. 
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Chapter 3 
Amyloid- Adopts a Conserved, Partially Folded Structure upon Binding to 
Zwitterionic Lipid Bilayers Prior to Amyloid Formation 
This chapter was adapted from the following publication: 
 Korshavn, K. J., Bhunia, A., Lim, M. H., Ramamoorthy, A. Amyloid- Adopts a 
 Conserved, Partially Folded Structure upon Binding to Zwitterionic Lipid Bilayers 
 Prior to Amyloid Formation.  Chem. Comm.. 52, 882-885 (2015). 
3.1. Introduction 
 Alzheimer’s disease (AD), one of the leading causes of death worldwide, is commonly 
considered a protein misfolding disease.
1
 While identified by the deposition of insoluble 
aggregates of amyloid- (A) peptides as plaques in the brains of diseased patients,1,2 it is 
presently thought that soluble, intermediate oligomers and the process of their interconversion 
are mostly responsible for neuronal death in AD.
3
 The interaction of these soluble A species 
with the lipid bilayer of neurons is believed to be responsible for toxicity, through both the 
formation of ion-selective channels as well as more dramatic membrane permeabilization and 
disruption via a two-step mechanism.
4
 Preventing such toxic interactions and structural 
transitions could be an important strategy for blocking A toxicity in AD. Unfortunately, high 
resolution mechanisms of peptide interaction with both itself and the cell membrane are unclear 
due, in large part, to the heterogeneous protein environments present during amyloid formation.
5
 
To date, most full length structural models of A explore the structure of mature fibrils.6-9 
Monomeric and early soluble oligomers have also been investigated, though it is believed that 
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the monomer exists as a predominantly disordered backbone and most oligomers are too 
transient to garner significant structural data.
5,10,11
 Most structured, low molecular weight 
structures are the result of stabilization of detergents and other micellular structures.
12-15
 While 
these models provide insight about how A prefers to partition between hydrophobic and 
hydrophilic environments, detergents are not a viable mimetic for biological membranes and the 
concentration and identity of the detergent can drastically impact the aggregate structure which 
raises questions of the physiological relevance of these structures. Greater understanding of in 
vitro intermediate structures adopted by A, specifically within the biological context of intact 
lipid bilayers, is necessary to fully elucidate its in vivo aggregation pathways and toxic 
mechanisms. 
 High resolution structural insights into the membrane-associated A species have been 
elusive to date. Recent developments in solid-state NMR have enabled some initial insights into 
some of the mechanisms and structures associated with late stages of membrane-associated A 
aggregation.
16-18
 The heterogeneity of early aggregation events makes them extremely difficult to 
investigate, however, and they remain poorly understood. It remains possible to apply solution 
NMR methodologies to interrogate early stages of membrane-A40 interaction. NMR, however, 
is hindered by both the large size of vesicle membrane models, which can broaden the lipid-
bound protein signal beyond detection, and the ability of membranes to accelerate the 
aggregation of A, reducing the free monomer concentration and limiting its intensity while 
simultaneously generating solution NMR invisible proteinaceous species.
19,20
 It has been 
previously shown, however, that maintaining a static sample at lower temperature stabilizes the 
monomeric peptide
21
 while using 100 nm large unilamellar vesicles (LUVs) composed solely of 
zwitterionic phosphatidylcholine (PC), containing lipids limits membrane-mediated catalysis of 
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amyloid formation while still allowing protein-membrane interactions.
20
 Additionally, transfer- 
and relaxation-based solution NMR experiments are specifically designed to allow for the 
interrogation of lowly populated, transient states, traits which exemplify the early membrane-A 
intermediates.
22
 The use of zwitterionic lipids to considerably reduce the lipid bilayer binding 
affinity of the peptide enabled us to measure the secondary structure of the bilayer-bound peptide 
by promoting exchange between the free and bound populations of A40 and decreasing the 
membrane-associated aggregation of Ab which is promoted by the presence of net charge on 
model membranes. Herein, coupling non-aggregating A40 sample preparations with a suite of 
NMR experiments
22,23 
and other biophysical approaches, we are able to successfully investigate 
the effect of early membrane interactions on the structure of A40 prior to its aggregation on the 
bilayer surface and identify a conserved, partially helical structure which is adopted upon 
binding to the lipid bilayer.  
3.2. Results 
3.2.1. Sample optimization 
 The interaction of A40 on the bilayer surface was probed with LUVs composed entirely 
of dilauroyl phosphatidylcholine (DLPC), dioleoyl phosphatidylcholine (DOPC), or 1-palmitoyl-
2-oleoyl phosphatidylcholine (POPC) (Fig. 3.1). All three lipids form a liquid crystalline, 
zwitterionic bilayer above 0 °C while having variations in their hydrophobic thickness.
24,25 
In so 
doing, we investigated the universality of binding events to fluid PC bilayers which have 
variations in degrees of unsaturation and hydrophobicity. Additionally, it has been suggested that 
lipid bilayers of diseased neurons in AD may be noticeably thinner than their non-diseased 
counterparts. The prevalence of oxidative stress in the AD brain is capable of generating short-
chain lipids through peroxidation of unsaturated acyl chains.
26-28
 Additionally, protein 
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aggregation on membranes, like that of A, can induce local thinning via mechanical strain.29-31 
Thus, while exploring general mechanisms of peptide interactions at membrane surfaces, it may 
also be possible to glean a structural understanding of the role which pathogenic membrane 
thinning plays in AD. 
 
Figure 3.1. Zwitterionic lipid structures. All lipids used in this study contain the zwitterionic 
phosphatidylcholine (PC) head group. They differ in their acyl chain length which determines the 
hydrophobic thickness (20.9-27.1 Å),
24,25
 but does not dramatically impact their transition 
temperature (Tm), ensuring that all bilayers are in the liquid crystalline phase under our 
experimental conditions. 
 Upon the addition of substoichiometric concentrations of LUVs to A40, circular 
dichroism (CD) suggests that the majority of the peptide is disordered in the presence of all three 
different bilayer systems, as has been previously suggested.
32
 This predominantly unstructured 
state remains stable for at least 24 h under quiescent conditions suggesting the peptide remains 
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predominantly monomeric over the course of incubation (Fig. B.1). While the unchanged CD 
spectra show a bulk population which is unstructured and likely unbound from the bilayer,  
observing the same conditions by 
1H NMR reveals global broadening of the peptide’s resonances 
following the addition of LUVs of each unique lipid composition to the peptide (Fig. B.2). Line 
broadening is suggestive of exchange between free, NMR-visible peptide and some form or 
forms of lipid-associated, NMR-invisible peptide on the NMR time scale. The existence of this 
invisible state solely in the presence of LUVs indicates the formation of an A40–bilayer 
complex and suggests that there is a sub-population of the peptide which exists in a structured or 
semi-structured, membrane-bound conformation which is overpowered by the bulk peptide’s 
random coil conformation in CD measurements.  
3.2.2. tr-NOESY provides structural insights 
 Due to the evident fast exchange of A40 between the free and membrane-associated 
states, transferred 
1
H–1H nuclear Overhauser effect spectroscopy (tr-NOESY) was applied to 
probe the conformational changes induced by peptide-bilayer interactions while filtering out 
structural information from the unbound population of A40.
33-35
 Traditionally, peptides and 
proteins associated with large lipid bilayer mimetics are difficult to investigate with traditional 
solution NMR spectroscopy due to their long correlation times and subsequent signal 
broadening. However, when the peptide of interest is in exchange between its bound and free 
forms, as it is in our A40 system, tr-NOESY is able to provide NOEs between protons from the 
bound state via observation of the free A40 population, thus overcoming the traditional signal 
broadening limits.  
 The obtained tr-NOESY spectra of A40 in the presence of all three vesicles present a 
large number of NOEs which suggest the existence of an at least partially folded structure when 
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bound to each PC-containing LUV (Fig. 3.2). Furthermore, similar NOEs originating from the 
peptide were observed with all three different LUV types, implying that the partially folded 
conformation of A40 bound to the lipid bilayer is similar across DLPC, DOPC, and POPC 
bilayers (Fig. 3.3a). This demonstrates that initial interactions between A40 and the lipid  
 
Figure 3.2. Select regions of tr-NOESY spectra of A40 (80 M) in the presence of LUVs. The 
NH–H region of the tr-NOESY spectrum in the presence of LUVs (a) DLPC, (b) DOPC, or (c) 
POPC (16 M lipid)(Bruker 900 MHz spectrometer using 80 ms mixing time, equipped with 
cryoprobe at 10 C; 20 mM PO4, pH 7.4, 50 mM NaCl). Moderate broadening of peaks hinders 
complete resonance assignment, but suggest a modest exchange rate between the lipid-bound and 
-free forms of the peptide.  
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membrane may, therefore, be predominantly controlled by the surface characteristics of the 
membrane (charge and head group) rather than hydrophobic characteristics (acyl chain saturation 
and thickness). The N-terminal residues (D1-Q15) show few NOEs, signifying a greater degree 
of flexibility relative to the rest of the peptide for which additional NOEs are observed. It is 
likely, therefore, that the N-terminus of A40 plays a minimal role in early adsorption to the 
bilayer surface and is not initially associated with the membrane. Sequential NH–NH and H–
NH NOEs are prominent throughout the central region (K16-G25) of the A40 peptide, indicating  
 
Figure 3.3. tr-NOE derived structural constraints for A40. (a) NOE connectivity plot shows a 
partially structured backbone conserved across all three different bilayers investigated. The 
strengths of NOEs are indicated by the height of the bars, graded as strong, medium, or weak. 
The H

 chemical shift for (b) DLPC, (c) DOPC, and (d) POPC was calculated for each resolved 
residue relative to the random coil chemical shift for each residue. 
91 
 
enhanced rigidity and a propensity for secondary structure. This region has previously been 
found to adopt a partially folded, 310 helix in solution
10
 while also being proposed to instigate the 
formation of amyloid fibrils as a self-recognition sequence.
1
 A second string of sequential NH–
NH and H
–NH NOEs was seen for the more C-terminal hydrophobic region (G29-M35) which, 
similarly to the self-recognition sequence, has been implicated in fiber structure and formation.
1
 
Along with these sequential NOEs, multiple H
–Hi,i+4 NOEs were observed in the central 
sequence (L17-A21, V18-E22). These side chain NOEs are accompanied by an H
–NH i,i+5 
NOE between L17 and E22. This combination of i,i+4 and i,i+5 NOEs is suggestive of the 
peptide folding into a loosely packed -helix in the central region.  
 In conjunction with these long distance NOEs, frequent negative ∆H values (Fig. 3.3) 
are predictive of a general helical propensity (Fig. 3.3b-d). Sequential helical propensity is most 
pronounced between K16 and E22 region, which, along with the NOE connectivity observed 
above, further supporting that the central portion of A40 adopts a helical conformation in the 
presence of all three PC bilayers upon binding. The presence of multiple, non-sequential 
negative ∆H values in the more C-terminal region may demonstrate a propensity toward a more 
random coil and rigid membrane associated conformation. Finally, the N-terminus displays few 
resonances in the presence of all three bilayers, indicating weak or no interaction with the lipid 
bilayer and a lack of defined structure or rigidity.  
3.2.3. Probing membrane associated backbone topology 
 In order to better define the boundaries of membrane-bound and -unbound regions of the 
peptide, paramagnetic MnCl2 was titrated into a solution of 
15
N-A40 in the presence of the three 
different LUVs and SOFAST-HMQC spectra were recorded to observer the backbone amide 
signals. The paramagnetic Mn
2+
 ion is capable of selective quenching NMR signals from solvent 
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exposed residues not associated with the hydrophobic lipid bilayer (Fig. B.3). As was observed 
with tr-NOESY, A40 in the presence of each of the three lipid bilayers reacted similarly to the 
presence of MnCl2. Substoichiometric concentrations of MnCl2 (40 M) reduced the signal 
intensity of the N-terminus (D1-Q15) to ca. 50% of their original value while stoichiometric 
concentrations (80 M) decreased the same regions to ca. 30% of their original intensity. The 
same concentrations of MnCl2 decreased the remainder of the peptide’s resonances to ca. 90% 
and 85%, respectively. This suggests that the N-terminal residues, predicted to be flexible and 
unassociated with the membrane based on tr-NOESY spectra, are, in fact, not bound to the 
bilayer surface and instead free and unstructured in solution. The remainder of the peptide is 
associated with the bilayer surface, though only adopting defined structure in selective 
hydrophobic regions, according to the tr-NOESY results. 
 The relaxation and dynamics of the peptide in the presence of LUVs were measured to 
further interrogate the membrane-associated and membrane-unassociated regions of the peptide 
sequence. 
15
NH-R2 values (the difference in 
15
NH-R2 in the presence of LUVs versus in the 
absence) measure the relative flexibility of the peptide backbone in the presence of PC bilayers. 
As a protein becomes more rigid or solid-like, its transverse relaxation rate (R2) increases as 
spin-spin relaxation becomes more likely. It is expected that regions of the peptide which 
preferentially interact with the lipid bilayer will present an increase in their R2 values relative to 
peptide free in solution. Interestingly, unlike what was observed in the tr-NOESY and PRE 
experiments above, the three lipids induced different dynamic changes to the peptide backbone 
suggesting a difference in the extent of lipid-peptide interaction that contributes to the rigidity of 
the residues in the structured region of the peptide, as discussed below (Fig. 3.4). Instead of each 
bilayer selectively increasing the relaxation rate (R2) of the bound, structured region, there was 
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no sequence specificity for the relaxation increases observed; the increases were sporadic 
throughout the peptide sequence. Additionally, the average R2 differs for each of the three lipid 
systems. This suggests that the relaxation changes are not due to specific structural alterations 
and are instead the result of differential binding propensities and partitioning of free versus 
bound peptide to the three different bilayers. Fluorescence polarization was used to measure the 
binding affinity (Kd) of the peptide for the three distinct LUVs (Fig. B.4). There was an inverse 
correlation between bilayer thickness (Fig. 3.1) and the measured affinities (DLPC, 20.9 Å, Kd = 
1188 ± 41 M; DOPC, 26.8 Å, Kd = 801 ± 45 M; DLPC, 27.1 Å, Kd = 366 ± 36 M). An  
 
Figure 3.4. Peptide backbone dynamics in the presence of lipid bilayers. The R2 value for each 
resolvable residue was calculated as the difference between the relaxation of A40 in the 
presence LUVs containing either (a) DLPC, (b) DOPC, or (c) POPC and A40 free in solution. 
The average R2 of all residues of the peptide is represented by the dashed gray line. 
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additional inverse correlation exists between the R2 values and the binding affinity of A40 for 
each bilayer (Fig. B.5). Therefore, the increase in rigidity and subsequently accelerated 
relaxation rates observed for the peptide are the result of an increased population which binds to 
the bilayer surface rather than a result of the structural changes induced by peptide binding. It is 
likely that the bound peptide is adopting the relaxation rate of the LUV itself and the higher the 
population bound with LUV the more the R2 value increases as the weighted average R2 value 
for all species of peptide shifts to faster rates. It is also worth noting that this is the only 
parameter which correlates with the bilayer thickness. The thicker the membrane, the stronger 
the affinity and the more rigid the peptide population becomes. While the partially 
foldedstructure of A40 is conserved across bilayers, it may be that the increased hydrophobic 
thickness of the POPC membrane is more capable of stabilizing this transient species. 
3.3. Discussion 
 It seems, therefore, that zwitterionic, liquid crystalline bilayers are capable of inducing a 
conserved fold in A40, tuneable by small alterations in the bilayer structure (i.e., thickness and 
acyl chain saturation). In this common fold, the N-terminus is unstructured and unassociated 
with the membrane, while the more C-terminal region adopts a bound, more rigid coil structure 
and the central hydrophobic region become a more structured helix (Fig. 3.5.). This general 
topology is similar to both a previously proposed structure of partially folded A40 in solution
10
 
and a model of A40 bound to GM1 micelles.
12
 It is, then, possible that this conserved helical 
fold may extend beyond PC bilayers and be a more universal early step in A40 folding and 
aggregation. General helical intermediates have previously been suggested, especially in the 
presence of heterogeneous bilayers, though the residue-specific topology is unclear in most 
cases.
12,32,36
 We believe that this helical, membrane bound intermediate may represents the first  
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Figure 3.5. Structural modelling of membrane-bound A40. (a) A40 adopts a conserved binding 
mode with PC lipid bilayers. Those residues in black circles are believed to have an especially 
high propensity for structure based on observed tr-NOEs. 3D cartoon models were generated 
based on tr-NOE and paramagnetic quenching constraints for (b) DLPC, (c) DOPC, and (d) 
POPC lipid bilayers. (e) The folding of A40 on the bilayer into this conserved helix likely 
precedes the formation of other membrane-associated aggregate species related to membrane 
disruption. While monomer association happens almost instantaneously, pore formation occurs 
over the course of minutes, and fiber-mediated disruption occurs over the course of hours, it 
remains unclear whether one event proceeds from the previous or whether these events are 
decoupled.
4
 
step in membrane-mediated A aggregate formation, preceding both transmembrane pore 
formation and surface-catalyzed fiber formation and subsequent membrane disruption (Fig. 
3.5e).
4
 Our results suggest that the central region containing the self-recognition sequence of 
A40 (K16-E22) commonly associated with the cross -strand amyloid structure may also be 
essential for the formation of early helical intermediates. In this model, we assume that 
membrane-associated oligomers form as the result of interactions between monomeric subunits 
on the bilayer, rather than forming in solution and subsequently inserting into the bilayer to enact 
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their function. It is necessary to further explore this possible mechanism further. It is likely that 
similar investigations to those performed here with bilayers that vary in their fluidity may be able 
to further clarify the role of membrane mediated aggregates versus aggregates which form in 
solution and subsequently associate with or insert into the membrane.  
 Additionally, it is interesting that, while it did not impact the surface-induced folded  
structure, bilayer hydrophobic thickness strongly influenced the affinity of the peptide for the 
bilayer and the population’s rigidity. It is known that membrane hydrophobic thickness is 
capable of modulating the insertion and folding of conventional membrane proteins.
37,38
 It is 
possible that our observed differences in binding affinity, which take into account the entire 
population of A40, rather than solely the partially folded structure, are the result of higher order 
intermediates which we have no observed here preferentially associating with the bilayer. If this 
is the case, it suggests that the peptide could interact with conventional bilayers and 
pathologically thinned bilayers differently.
27,28
 While this study has only investigated the early 
monomer interactions with the bilayer, it will be advantageous to explore the effect of these 
altered affinities on the subsequent aggregation of A40 on membranes of varying thicknesses 
further. These studies may help explain relationships between two important physiological 
factors in AD. 
3.4. Materials and methods 
3.4.1. Materials 
Unlabeled A40 (> 95% purity) was purchased from Genscript (Piscataway, NJ, USA). 
Uniformly 
15
N-labeled A40 was purchased from rPeptide (Bogart, GA, USA). HiLyte Fluor 
647-A40 was purchased from Anaspec (Fremont, CA, USA). All peptide was used as received 
without additional purification. 1,2-Dilauroy-sn-glycero-3-phosphocholine (DLPC), 1,2-
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dioleoyl-sn-glycero-3-phosphocholine (DOPC), and 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) were purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA). 
All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).  
3.4.2. Vesicle preparation 
Large unilamellar vesicles (LUVs) of pure DLPC, DOPC, and POPC were prepared from a 
chloroform solution. The resulting solution was dried under N2 (g) and then placed under high 
vacuum overnight to remove the residual solvent. The resultant film was rehydrated with buffer 
solution (20 mM PO4, pH 7.4, 50 mM NaCl) to yield a final lipid concentration of either 10 
mg/mL (for fluorescence binding experiments) or 1 mM (for all other experiments). Lipid was 
resuspended by vigorous mixing and the resulting solution was extruded 23 times through a 100 
nm polycarbonate Nucleopore membrane filter (Whatman) mounted on a mini-extruder (Avanti 
Polar Lipids Inc.) to obtain a homogenous solution of LUVs with an average diameter of 100 
nm. The formation of vesicles was confirmed by dynamic light scattering to ensure solution 
homogeneity. 
3.4.3. Peptide preparation 
 In order to break up preformed aggregates in the initial peptide aliquot, both unlabeled 
and uniformly 
15
N-labeled peptide was dissolved in 1% NH4OH and aliquoted to 0.1 mg/sample, 
and lyophilized. HiLyte Fluor 647-A40 was similarly dissolved in 1% NH4OH and aliquoted to 
0.01 mg/sample and lyophilized. All peptide was dried under vacuum for 48 h to remove excess 
moisture.  
3.4.4. Circular dichroism studies 
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Circular dichroism (CD) measurements were carried out at a concentration of 20 M 
A40 in the presence of 4 M LUV in buffer (20 mM PO4, 50 mM NaF, pH 7.4). Freshly 
lyophilized peptide was first dissolved in 5 L of 1% NH4OH prior to dilution into the buffer to 
prevent the formation of early aggregates. CD measurements were performed on a JASCO J-
1500 CD Spectrometer using a 0.1 cm path length cell. The spectra were acquired at 10 °C at a 
scan rate of 100 nm/min and averaged over 10 scans. Measurements were taken immediately 
after mixing the sample (t = 0 h), after 4 h incubation at 4 °C, and after 24 h incubation at 4 °C. 
3.4.5. Fluorescence anisotropy binding studies 
To prepare the peptide for fluorescence experiments, HiLyte Fluor 647-A40 was 
dissolved in 5 L 1% NH4OH and diluted into buffer (20 mM PO4, pH 7.4, 50 mM NaCl) to a 
final peptide concentration of 1 M. Fluorescence measurements were performed on a Jasco FP-
6500 fluorimeter equipped with excitation and emission polarizing filters. Fluorescence 
polarization was used to measure the binding affinity of A40 for 100 nm LUVs of the various 
lipids. 150 L of a 1 M solution of HiLyte Fluor 647-A40 was titrated with LUVs from a 10 
mg/mL stock solution. Lipid was titrated into peptide solution to a maximum concentration of 7 
mM. The fluorescence anisotropy was monitored with an excitation wavelength of 647 nm and 
emission wavelength of 660 nm using a 10 nm bandwidth for both excitation and emission at 
each titration point. Anisotropy (<r>) was calculated using equation 1 where G is defined by 
equation 2. I is the intensity observed with excitation (first subscript) and emission (second 
subscript) polarizers set to either vertical or horizontal, providing four measurements which 
contribute to the anisotropy calculation.  
< 𝑟 > =  
𝐼𝑉𝑉−𝐺∗𝐼𝑉𝐻
𝐼𝑉𝑉+2∗𝐺∗𝐼𝑉𝐻
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(1) 
𝐺 =
𝐼𝐻𝑉
𝐼𝐻𝐻
  
( 2) 
 The anisotropy values measured were then plotted against their respective lipid 
concentrations and the data were fit using equation 3 to identify the binding affinity (Kd) of 
peptide for the LUVs.  
< 𝑟 >=
<𝑟>𝑖𝑛𝑓∗[𝑙𝑖𝑝𝑖𝑑]
𝐾𝑑+[𝑙𝑖𝑝𝑖𝑑]
+< 𝑟 >0  
(3) 
3.4.6. NMR spectroscopy 
For all samples analyzed by NMR, 0.1 mg peptide (uniformly 
15
N-labeled or unlabeled) 
was dissolved with 3 L DMSO-d6 (Cambridge Isotope, Tewksbury, MA, USA) and diluted with 
phosphate buffer, NaCl, D2O, and ddH2O to a final peptide concentration of 80 M (20 mM PO4, 
pH 7.4, 50 mM NaCl, 7% v/v D2O). For those samples containing lipid, LUVs were also added 
from a 1 mM stock solution containing a single lipid for a final lipid concentration of 16 M (0.2 
equiv). For all experiments, spectral were processed using Topspin 2.1 (Bruker) while 
assignments and intensity fits were performed by SPARKY 3.113. 
3.4.6.1. Transfer-NOESY (tr-NOESY) 
 Line broadening was first observed by 1D 
1
H
 
NMR upon the addition of 0.2 equiv (16 M) 
lipid, suggesting exchange between unbound and bound species; this peptide:lipid ratio was 
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utilized throughout for lipid containing NMR samples and was observed to be stable over the 
course of the experiments. Therefore, transfer-NOESY (tr-NOESY) experiments were carried 
out on Bruker TCI 900 spectrometer, equipped with a cryo-probe to investigate the membrane 
bound state of unlabeled A40 to the three LUVs.
33-35
 Two-dimensional (2D) 
1
H-
1
H TOCSY and 
1
H-
1
H tr-NOESY spectra were acquired at 80 and 150 ms mixing times, respectively at 10 °C. 
Tr-NOESY spectra were acquired using 2 K data points in t2 and 512 data points in t1 and a 
spectral width of 12 ppm in both dimensions. H

 chemical shifts were then calculated relative to 
the random coil shift values maintained by the Biological Magnetic Resource Bank (BMRB, 
University of Wisconsin). 
3.4.6.2. Paramagnetic relaxation enhancement titration 
 A solution of MnCl2 was titrated into a solution of uniformly 
15
N-labeled A40 in the 
presence of LUVs described above and monitored by SOFAST-HMQC on a Bruker 600 MHz 
spectrometer equipped with a cryoprobe at 10 °C. Spectra of each sample in the presence of 0 
equiv (0 M), 0.5 equiv (40 M), and 1 equiv (80 M) MnCl2 were obtained from 128 t1 points 
and a 100 ms recycle delay. Relative intensities for all spectra were obtained by a comparison of 
spectra in the presence of spectra acquired in the presence of both 0.5 and 1.0 equiv MnCl2 to 
spectra in the absence of the paramagnetic reagent. Peak assignments for the spectra were based 
on previously published spectra.
10
 
3.4.6.3. Relaxation measurements 
 The 
15
N transverse relaxation rate constants (R2 = 1/T2) for the residues of A40 were 
determined by collecting a series of 
15
N-
1
H HSQC spectra under a variety of relaxation delays on 
a Bruker 600 MHz spectrometer equipped with a cryoprobe at 17 °C using the uniformly 
15
N-
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labeled A40 samples described above; R2 values were measured for samples in the presence of 
all three different bilayers, as well as in the absence of lipids. Relaxation delays of 8, 16, 32, 48, 
64, 80, 96, 128, 160, 194, 240, and 320 ms were used for the measurement of R2. R2 values 
were then calculated as the difference between the R2 values of peptide in the presence of the 
three LUVs (DLPC, DOPC, and POPC) and the R2 values of peptide in the absence of lipid. 
Positive R2 values are indicative of a protein population which is more rigid than the peptide 
population in the absence of lipid while negative R2 values are indicative or a less rigid 
population. 
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Chapter 4 
Reduced Lipid Bilayer Thickness Regulates the Aggregation and Cytotoxicity 
of Alzheimer’s Disease Related Amyloid- 
The content for this chapter will be included in the following reference: 
 Korshavn, K. J., Satriano, C., Zhang, R., Lin, Y., Dulchavsky, M., Bhunia, A., Ivanova, 
 M., Lee, Y. –H., La Rosa, C., Lim, M. H., Ramamoorthy, A. Reduced Lipid Bilayer 
 Thickness Modulates the Aggregation of and Ablates the Cytotoxicity of A. Submitted. 
4.1. Introduction 
 The aggregation and fibrillation of amyloid- (A) in the brain has long been implicated 
in the neurotoxicity and pathogenesis of Alzheimer’s disease (AD). Following its production via 
cleavage of the transmembrane amyloid precursor protein (APP), A undergoes aggregation 
along a nucleated growth pathway towards its end state amyloid fibril.
1
 It is believed that 
intermediate aggregates along this path are the primary culprit in AD-related cytotoxicity.
2,3
 
Early A oligomers may perform their toxic function through interactions with the neuronal lipid 
bilayer.
4,5
 Pore formation has been suggested to facilitate disruption of the ionic gradient across 
neuronal membranes.
6,7
 Alternatively, elongation of the amyloid species on the bilayer may 
remove lipids from the membrane and create holes which allow for the uncontrolled transit of 
biomacromolecules across the membrane.
8,9
 These two modes of membrane disruption have been 
proposed to coexist; it is thought that pore-like oligomers form first while the fibril-induced 
perturbations occur later.
8
 Extensive work by Matsuzaki and colleagues has revealed that 
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incorporating glycolipids, such as the ganglioside GM1, can promote the formation of toxic, 
membrane-associated A aggregates linked to membrane disruption.5 Despite these insights, the 
overarching biological, chemical, and physical parameters that govern the interactions of A 
with lipid bilayers and modulate the formation of toxic oligomers remain unclear.  
 Bilayer thickness, controlled by the acyl chain length, is one basic principle of membrane 
biophysics that has been shown to alter membrane protein folding and modulate energetic 
penalties caused by the hydrophobic mismatch.
10,11
 It is therefore possible that alterations in the 
hydrophobic thickness can control amyloid aggregation and stabilize distinct intermediates. 
Short chain lipids may form within the AD-affected brain via lipid peroxidation promoted by the 
heightened oxidative stress found in the diseased state.
12-14
 Incorporation of these shortened 
lipids can be toxic and result in localized bilayer thinning.
13,14
 The interaction of amyloidogenic 
sequences with lipid membranes and their aggregation in bilayers can also reduce local bilayer 
thickness via mechanical strain.
15-17
 Thus, characterizing the effects of thin bilayers on A 
aggregation is of great importance for understanding the underlying physical parameters that 
drive misfolding and unveiling the roles of pathologically relevant A-membrane interactions in 
AD. Herein we have used synthetic bilayers composed of dilauroyl phosphatidylcholine (DLPC; 
20.9 nm thick), dioleoyl phosphatidylcholine (DOPC, 26.8 nm thick), or 1-palmitoyl-2-oleoyl 
phosphatidylcholine (POPC, 27.1 nm thick) to explore relationships between thin (DLPC) and 
thick (DOPC and POPC) bilayers, A aggregation, and the stabilization of distinct A 
oligomers.
18,19
  
 Using the thin DLPC can recapitulate the potential thin bilayers of the diseased cells within 
an in vitro setting while ensuring reproducibility. We have previously shown that monomeric A 
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interacts with these three zwitterionic lipid bilayers through a conserved structure under non-
aggregating conditions.
20
 This initial binding is driven by surface interactions with the self-
recognition sequence and is minimally affected by the hydrophobic thickness of the membrane. 
It is more likely that the hydrophobic thickness of lipid bilayers influences the generation and/or 
stabilization of higher order membrane-associated species because of the ability of these A 
aggregates to insert themselves within the bilayer.
21
 Both DOPC and POPC have been previously 
applied to examine the interactions between lipid bilayers and amyloidogenic proteins.
8,22-25
 
DLPC bilayers have been used in the study of a variety of membrane proteins and were observed 
to stabilize some membrane proteins in vitro, which are less tractable with other lipid bilayer 
systems, but they have not previously been used in the study of A26,27  
 Through a suite of biophysical techniques we have found that the thin, pathology-
mimicking DLPC bilayers have a unique ability to stabilize prefibrillar oligomers within the 
bilayer while preventing the formation of mature fibrils. Surprisingly, it was observed that DLPC 
bilayers are also capable of remodeling mature A fibrils into a semi-unfolded intermediate, a 
feat previously observed only after treatment with high concentrations of denaturants or exposure 
to high frequency sonication.
28
 These results show that thin bilayers are able to dramatically alter 
A aggregation compared to conventional lipid bilayers, and this redirected misfolding can 
stabilize distinct, membrane-associated species not previously observed.  
4.2. Results 
4.2.1. Unlike DOPC or POPC, DLPC Vesicles Inhibit A Fibrillation 
 Lipid bilayers can modulate the rate of amyloid formation by A, though the extent of 
modulation varies with the bilayer composition, incubation conditions, and detection method.
29-31
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Thioflavin-T (ThT), a dye which fluoresces in the presence of amyloid fibrils, can probe the 
formation of fibrillar aggregates and is useful in delineating mechanistic deviations in amyloid 
aggregation.
32-34
 Thus, ThT was used to initially probe the aggregation propensity of Ain the 
presence of large unilamellar vesicles (LUVs) of either DOPC, POPC, or DLPC and characterize 
kinetic differences that result from different interactions caused by variation in hydrophobic 
thickness.  
 A aggregation was accelerated by increasing concentrations of either DOPC or POPC 
(Fig. 4.1a-c), as previously reported.
29,30
 As the lipid concentration increased from 0 to 200 M, 
the lag phase became continually shorter, suggesting more rapid nucleation and earlier fibril 
formation. It is likely that the observed catalysis is the result of interactions between A and 
membrane, which serve to reduce the dimensionality of the search by individual A monomers 
for binding partners and increase the local A concentration.29 End state aggregates formed in 
the absence and presence of either DOPC or POPC were examined by circular dichroism (CD) 
spectroscopy and transmission electron microscopy (TEM) (Fig. C.1). As expected, all three 
samples exhibited a canonical peak at 220 nm in CD spectra, representative of a -strand fold 
and amyloid formation. TEM further established the generation of fibrillar aggregates. Fibrils 
formed in the presence of DOPC or POPC are shorter than those formed in solution. This 
discrepancy in length may be due to the effects of increased local concentration on the bilayer 
surface, generating additional seeds for aggregation resulting in fewer free monomers available 
for the extension of the fibrils. These data support previous studies suggesting that both DOPC 
and POPC act as amyloid catalysts.
29,30
 
 Incubation of DLPC LUVs with A elicited a dramatically different result compared to  
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Figure 4.1. Effect of 100 nm phosphatidylcholine LUVs on A aggregation kinetics. Both 
DOPC (a) and POPC (b) accelerate A (10 M) aggregation in a concentration dependent 
manner as determined by ThT (20 M) fluorescence. (c) The lag phases suggest that kinetic 
acceleration is most potent at 500 M lipid, though aggregation is rapidly accelerated at 
concentrations as low as 50 M lipid. (d) DLPC LUVs inhibit A aggregation at stoichiometric 
and super stoichiometric concentrations. (e) Low concentrations of DLPC (nM range) accelerate 
A aggregation before reaching concentrations that eventually inhibit fibrillation. (f) The lag 
phase of A aggregation in the presence of DLPC LUVs reaches a maximum acceleration at ~ 
500-700 nM. Lag phases reported represent the average of three independent trials with error 
bars representing the standard deviation of these measurements.  
DOPC or POPC (Fig. 4.1d). When A aggregated in the presence of stoichiometric (10 M; 1:1 
lipid-peptide ratio) or higher DLPC concentrations, ThT fluorescence remained at baseline levels 
suggesting no fibril formation. ThT can provide false positives of inhibition resulting from dye 
displacement or the inability of unique amyloid sequences to bind ThT despite containing the 
canonical -strand fold.35,36 To rule out this possibility, CD and TEM were performed on 
endstage aggregates (Fig. C.1). CD results showed that the species formed in the presence of 
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DLPC maintained a random coil structure after 24 h incubation. The aggregates were also 
morphologically distinct from conventional amyloid fibrils. They were small, amorphous, and 
had no discrete fibril structure, as shown by TEM. Combined with ThT results, we confirmed 
that stoichiometric concentrations of DLPC LUVs halt amyloid fibril formation of A.  
 To further characterize the potency of this inhibition, ThT was used to examine the kinetics 
of amyloid formation in the presence of substoichiometric concentrations of DLPC (Fig. 4.1 e 
and f). As DLPC concentration increased from 0 to 500 nM the lag phase of aggregation 
shortened, suggesting accelerated A fibrillation. Increasing the concentration beyond 700 nM 
lengthened the lag phase. Aggregation was halted by DLPC concentrations above 1 M. Similar 
kinetic profiles were observed in the presence of DLPC LUVs of different diameters, suggesting 
that the effect of DLPC on A aggregation is independent of bilayer curvature (Fig. C.2), unlike 
the effect of other model membranes.
31
 The profile by which DLPC initially accelerates and 
subsequently inhibits amyloid formation based on concentration is similar to the effect of 
detergents on amyloid formation.
37
 This suggests that free DLPC, existing in equilibrium with 
DLPC encapsulated in LUVs, may play a role in modulating A aggregation through a 
detergent-like mechanism. DLPC is able to act as a detergent with a very low critical micelle 
concentration (~100 nM).
38
 However, free DLPC only inhibited A aggregation at much higher 
concentrations than DLPC in LUVs (15 M; Fig. C.3 a and b). These results suggest that DLPC 
micelles are insufficient to explain the observed modulation of A aggregation. 
4.2.2. ABinding to DLPC Liposomes Induces Membrane Disruption and Unstructured 
Oligomers 
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 To clarify the extent to which detergent-like activity of free DLPC is capable of 
modulating A aggregation, it is essential to identify the source of free lipid. While there is an 
equilibrium between bilayer-inserted and free DLPC, this equilibrium is not capable of 
generating high concentrations of free DLPC in the absence of peptide.
39,40
 It has been shown, 
however, that interactions between amyloidogenic peptides and lipid bilayers can extract lipids 
and generate micelle-like particles.
8,41,42
 These species could exist as a result of A-DLPC 
interactions and subsequently play a role in the observed modulation of A aggregation.  
 
Figure 4.2. Membrane perturbations by A. (a) 31P solid-state NMR of 1000 nm LUVs (23 mM 
lipid) in the absence (black) and presence (red) of A (230 M). The anisotropic peak around -
15 ppm represents the intact liposomes while the small peak near 0 ppm in the DLPC+A 
spectrum (noted by an arrow) indicates the formation of small, rapidly tumbling lipid species 
suggestive of membrane fragmentation. (b) AFM was performed on SLBs of DLPC, DOPC, or 
POPC incubated in the presence of A as a function of time in order to observe both the 
deposition of A aggregates on the membrane and defects induced in the bilayer surface as a 
result of aggregation. 
112 
 
Differences between micelle-like lipid species and LUVs can be detected using 
31
P solid-state 
NMR.
8,42,43
 Due to their large size, intact vesicles of DLPC, DOPC, and POPC exhibit a powder 
pattern spectrum which spans from ~ -14 to ~ 25 ppm. Only the perpendicular edge (~ -14 ppm)  
of the spectrum is highly sensitive (Fig. 4.2a). Following incubation with A under aggregating 
conditions for 24 h a new peak centered near 0 ppm was observed for LUVs composed of DLPC. 
This isotropic peak at 0 ppm suggests a new, small, lipid structure induced by A(Fig. 4.2a). 
This provides a source for free DLPC; the interaction of A with the surface of DLPC liposomes 
is capable of removing lipids from the bilayer, despite the lack of fibrillation. This is unique both 
in the lack of fiber formation which has previously been suspected as the causative agent in 
amyloid-based membrane disruption and in the absence of GM1 ganglioside in the bilayer, a 
lipid which is believed to be needed for the disruption of neuronal bilayers.
5,8,41,42
 
 While the disruption of DLPC LUVs by nonfibrillar A species is novel, it is unlikely 
that the free DLPC generated is the sole cause of amyloid (Fig. C.3 a and b). A second 
mechanism of inhibition is necessary to explain the observed inhibition by DLPC LUVs. We 
initially hypothesized that changes in bilayer hydrophobic thickness may stabilize on and/or off 
pathway oligomers. To study intermediates formed on the surface of DLPC bilayers, we used 
atomic force microscopy (AFM) which is well suited for the interrogation and observation of 
bilayer-based aggregation of A7,44-47 After incubating monomeric Awith supported lipid 
bilayers (SLBs) of DOPC or POPC, early globular and prefibrillar oligomers were observed by 
AFM after 24 h in a liquid cell (Fig. 4.2b). While ThT data suggested that mature fibrils exist by 
this point in aggregation, AFM was performed under quiescent conditions which delays 
fibrillation.
48
 When DLPC SLBs were treated with A, a large number of globular aggregates 
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were present on the bilayer after 12 h. Aggregates persisted after 24 h of incubation, though the 
size of individual particles shrank. Defects in the membrane were also evident around the 
aggregates after both 12 and 24 h, suggesting that these aggregates perturb the bilayer integrity, 
in agreement with the 
31
P NMR results.  
 To quantify the membrane modification caused by A, the root mean square roughness 
(Rq) and average roughness (Ra) of the samples with respect to time were calculated based on the 
AFM data (Table 1). While all three bilayers initially formed with a similar smoothness and 
without defects, DLPC bilayers demonstrated a large increase in their roughness after 12 and 24 
h of incubation with A relative to both the initial bilayer smoothness and the observed 
smoothness for DOPC and or POPC SLBs. The increase in both Rq and Ra is caused by both the 
formation of aggregates as well as bilayer disruption. While Rq and Ra of DLPC bilayers 
decrease between 12 and 24 h of incubation, this is likely caused by aggregates equilibrating, 
becoming smaller and more evenly dispersed across the bilayer surface. To better understand the  
Sample Rq  S.D. (nm) Ra  S.D. (nm) 
DLPC 0.36  0.02 0.27  0.01 
+ A (12 h) 3  1 1.7  0.8 
+ A (24 h) 1.5  0.7 0.7  0.2 
DOPC 0.39  0.04 0.29  0.02 
+ A (12 h) 0.40  0.03 0.29  0.01 
+ A (24 h) 0.8  0.1 0.51  0.07 
POPC 0.49  0.03 0.39  0.03 
+ A (12 h) 0.5  0.1 0.27  0.06 
+ A (24 h) 0.8  0.5 0.4  0.2 
Table 4.1. Quantifying membrane perturbation. The root mean square roughness (Rq) and the 
average roughness (Ra) of SLBs incubated with A at different time points are calculated from 
the AFM images. 
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kinetics of the observed aggregate formation on the bilayer surface, AFM images were taken at 
early time points following Aaddition to DLPC SLBs (Fig. C.4). After just 5 minutes of 
incubation, holes were observed in the bilayer, indicative of dramatic disruption resulting from 
aggregation. Small, globular aggregates were also present. At later time points (15 and 20 
min)the aggregates grew in size while the membrane defects shrank slightly due to lipid 
diffusion within the membrane.  
 The AFM results point to a unique characteristic of DLPC bilayers. DLPC SLBs facilitate 
the rapid formation of globular aggregates on the bilayer surface of, and possibly within, the 
membrane. In contrast, most reports of membrane-mediated A aggregation using AFM 
demonstrate the formation of conventional fibrils.
45,49,50
 This membrane-associated aggregation 
is likely responsible for the bilayer disruption, despite not occurring through the canonical 
amyloid formation pathway. Amorphous aggregation occurring selectively on DLPC SLBs 
suggests that it is at least partly the result of DLPC’s uniquely small hydrophobic thickness. 
These globular species are stabilized by the short hydrophobic distance, which prevents their 
progression toward mature fibrils. There are, therefore, two mechanisms by which DLPC LUVs 
appear to inhibit the formation of A fibers. A-DLPC interactions generate micelle-like lipid 
species that can prevent aggregation; driving inhibition is the stabilization of globular, 
membrane-associated aggregates that are incapable of progressing toward fibrils.  
4.2.3. DLPC remodels mature A fibrils 
 While results to this point have illustrated how monomeric A may interact with and 
aggregate on bilayers of varying thickness, it is equally important to investigate how preformed 
aggregates may interact with these bilayers. The addition of DLPC LUVs to premade fibrils 
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caused a rapid reduction in ThT fluorescence in a dose-dependent manner (Fig. 4.3a). Similar 
fluorescence reduction has previously been observed in small molecule-induced disaggregation 
of various amyloid fibrils, suggesting that DLPC LUVs may alter the structure of the 
traditionally stable fiber.
51-53
 While ThT displacement is a possibility, the stabilization of the 
final fluorescence at ~40% of the original value, instead of returning to the baseline, suggests 
that ThT binding is maintained to some extent and that the changes are primarily structural.
35
 
Neither DOPC nor POPC LUVs caused a significant change in ThT fluorescence, suggesting that 
any structural changes to the fiber are specific to DLPC (Fig. 4.3b). The addition of free DLPC  
 
Figure 4.3. DLPC liposomes remodel preformed A fibrils. (a) When 100 nm LUVs of DLPC 
were added to preformed A fibrils (10 M monomer concentration; preaggregated for 24 h), 
ThT (20 M) fluorescence was decreased in a dose dependent manner. (b) The addition of 100 
nm LUVs of DOPC or POPC at much higher concentrations did not impact ThT fluorescence. 
(c) The CD spectrum of fibrillar A (30 M) was monitored following the addition of 100 nm 
LUVs of DLPC (300 M). (d) TEM images of the aggregates induced by incubating preformed 
A fibrils (30 M monomer concentration) with 100 nm DLPC LUVs (300 M lipid). 
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to preformed aggregates also minimally altered the ThT fluorescence of the aggregates, 
suggesting that the mechanism of remodeling is not through detergent-like effects (Fig. C.3c) 
 Assuming that the DLPC-induced fluorescence reduction is a function of structural 
changes, CD was used to examine the extent of these changes. Surprisingly, the -strand signal 
at 220 nm persists over the course of 24 h despite the observed reduction in ThT fluorescence 
stabilizing after 4 h (Fig. 4.3c). While seemingly contradictory, it has been previously 
demonstrated that amyloids can possess -strand content and be unable to bind ThT.36 Moreover, 
the TEM images of the preformed fibers treated with DLPC displayed a morphology distinct 
from mature fibers formed in solution (Figs. 3D and S1). The remodeled fibrils maintain some 
fiber-like characteristics, though they are much shorter and thinner than mature fibrils. These 
results confirm that DLPC LUVs are capable of remodeling mature A aggregates, though not to 
the extent of some traditional studies of disaggregation.
51-53
 
 There are, then, three likely mechanisms by which DLPC LUVs may remodel preformed 
A fibrils. (i) DLPC changes the monomer-fiber equilibrium and causes additional monomers of 
A to enter solution via dissociation from the ends of fibers, resulting in shorter aggregates.54 (ii) 
DLPC LUVs alter the hydrogen bonding network found within the fibril, generating distinct 
polymorphs of the aggregates which are less stable and can potentially become more similar to 
the immature protofibril structure.
54
 (iii) DLPC LUVs rearrange the side chain packing of the 
mature fibrils and induce a partially unfolded state without significantly altering the hydrogen 
bonding of the fiber core.
28
  
 We first explored the monomer-fiber equilibrium with 
1
H NMR. While monomeric Ais 
highly dynamic and yields strong signals in solution NMR, the fibrillar aggregates, due to their 
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large size and anisotropic tumbling, are essentially invisible (Fig. C.5a). This allows for the 
selective observation of monomeric and small, soluble intermediates over large species. It is also 
possible to correlate changes in signal intensity with the equilibrium between monomeric and 
aggregated A54 DLPC LUVs were added to fibrillar A and spectra were continually recorded 
for 23 h (Fig. C.5). While previous disaggregation studies using similar methods observed an 
increase in relative signal intensity over time during disaggregation, DLPC induced a minimal 
change in signal.
54
 This suggests that the monomer-fiber equilibrium is minimally perturbed and 
thus insufficient to explain the remodeling of preformed fibrils. This observation does not, 
however, rule out a change in other possible exchange equilibria which are invisible to solution 
NMR. It is known that fiber fragmentation rates can depend upon changes in solution conditions 
and are capable of producing small, protofibirl-like oligomers.{Knowles, 2009} These new, 
small aggregates would remain too large for solution NMR and thus cannot be ruled out as a 
possible mechanism. Additionally, if the dissociation event involves larger oligomers that exist 
between the monomer and protofibril, these too would be invisible to solution NMR and remain 
an alternative mechanism. 
 We next explored the possibility of DLPC altering the -strand topology of the fiber 
backbone and the stability which it imparts. It has been shown through extensive solid-state 
NMR studies that A fibers can adopt distinct backbone folds and polymorphs while maintaining 
the requisite -strand prominence and fiber core based on aggregation conditions.55-58 It is 
possible that DLPC LUVs could exert a chaperone-like activity to convert one fiber polymorph 
into another. We explored the differences between the structures using thermal unfolding 
experiments. If fibers treated with DLPC LUVs result in altered -strand folding and hydrogen 
bond networks their unfolding temperatures and enthalpy of unfolding will likely be different.
59-
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 To this end, we studied the stability of A fibers formed for 24 and 40 h, as well as fibers 
formed for 24 h and subsequently treated with either 5 or 20 equivalents of DLPC LUVs (Fig.  
 
Figure 4.4. Thermodynamic stability of A fibrils. A fibrils (20 M monomer concentration) 
formed after 24 h (a) and 40 h (b) were subjected to thermal denaturation and the -strand signal 
at 220 nm was observed as function of time. Similar denaturation experiments were performed 
on A fibrils formed by 24 h incubation and then treated with 5 equiv (c) or 20 equiv (d) of 100 
nm DLPC LUVs. After the fiber was unfolded by heating, the sample was cooled from 110 °C 
down to 25 °C and the structural signal was again observed for all four samples (marked by an 
x). These denaturation curves were fit to extrapolate both the melting temperature (Tm) (e) and 
the enthalpy of denaturation (H) (f) of the fibril under different conditions. 
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4.4). Samples were exposed to continuous shaking at 25 °C for the entirety of their aggregation 
and/or remodeling. All four samples exhibited similar melting temperatures (~ 68 °C) and 
enthalpies of denaturation (115-120 kJ mol
-1
). This thermal unfolding was also found to be 
irreversible, in agreement with other studies.
59
 The melting temperature is slightly lower than has 
previously been published for A40, likely due to different aggregation conditions, highlighting 
this method’s ability to distinguish distinct fiber polymorphs.59 The similarities in thermal 
denaturation suggest that, despite morphological differences based on TEM, the intermolecular 
forces responsible for aggregate stability are similar for all samples, and thus there is a low 
likelihood of distinct polymorphs being induced by the presence of DLPC. 
 It appears, then, that the DLPC-induced changes in ThT fluorescence and morphological 
differences observed by TEM are the result of more surface level disruptions. It has previously 
been shown that A fibrils can adopt a pseudo transition state, termed the molten globule state, 
in which side chain packing at the fiber surface becomes perturbed.
28
 The molten globule state 
was defined by a reduction in ThT fluorescence and truncation of the fibrillar structure while the 
-strand signal was maintained in CD spectroscopy, similar to what we have observed in the 
presence of DLPC (28). This molten globule state has previously been observed only following 
treatment of mature aggregates with ultrasonication. Treatment of fibrils with conventional 
chemical denaturants such as detergents or guanidine hydrochloride has previously resulted in 
the generation of the unfolded, monomeric form of A28 It is likely that DLPC is sufficiently 
mild in its perturbations so as not to fully denature and instead stabilize this unfolding transition 
state. While we observed that DLPC inhibits A aggregation through a combination of 
detergent-like interactions and stabilization of membrane associated globulomers, it is likely that 
the fibrils are primarily altered through interactions with the surface of DLPC LUVs which 
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promote disorder in the traditionally ordered side chain packing of the fibril.
28,62
 This increased 
disorder can facilitate a reduction in ThT binding and fluorescence. It may also increase the 
likelihood of A fibrils to fragment in order to compensate for the increased sidechain flexibility, 
explaining the truncated fibril structures observed by TEM.
63,64
 These two modes of disruption 
would be relatively independent of the main chain interactions and result in the maintenance of 
the conventional -strand structure, resulting in an aggregate species which resembles a 
protofibrillar structure.
65,66
 
4.2.4. Effect of lipid-A aggregates on cell viability 
 Having shown that DLPC LUVs are capable of generating two distinct, non-fibrillar A 
aggregates when the lipids are present, the biological function of these two different species 
becomes of interest. It has been proposed that oligomers act as the toxic agent in amyloid-related 
diseases, and different oligomers can enact various toxic functions.
2,3
 Stabilizing and 
characterizing the formation of many of these oligomers has been difficult, however. We 
therefore examined the toxic effects of stable species induced by pre-incubating monomeric A 
with DLPC LUVs as well as those species generated by treatment of mature fibrils with DLPC 
LUVs (Fig. 4.5 a and b). A aggregates formed in the absence of DLPC were observed to reduce 
cellular viability by ~50%. Aggregates formed in the presence of DLPC, however, were found to 
be nontoxic (Fig. 4.5a). This further suggests that these Aoligomers formed in the presence of 
DLPC LUVs are off-pathway aggregates. A fibrils remodeled by DLPC were found to induce 
cellular death to a similar extent as the untreated Aaggregate, suggesting that these molten 
globule aggregates resemble an on-pathway protofibrillar species, which has been suggested to 
be toxic.
66
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4.3. Discussion 
 While DLPC is not a lipid commonly found in eukaryotic membranes, it serves as a 
simplified model for membrane thinning associated with AD.
13,14,16,17
 Our findings suggest that 
these thin bilayers serve to inhibit the formation of A amyloid fibers instead by stabilizing 
disordered aggregates on the bilayer surface (Fig. 4.5c). This interaction, in turn, induces 
membrane disruption that causes lipids to shed from the bilayer and form micelle-like species 
above the CMC of DLPC. DLPC membranes are capable of reorganizing the surface and side  
 
Figure 4.5. Function and identity of DLPC-induced A aggregates. (a) A (2.5 M) aggregates 
were generated in the presence and absence of 100 nm DLPC LUVs and their toxicity against 
PC12 cells was compared by the MTT assay. (b) The toxicity of preformed A aggregates 
subsequently incubated with 10 equiv (25 M) DLPC. (c) The combined data from this study 
suggest that DLPC has two distinct modes of action against A aggregation (orange pathway). 
When DLPC LUVs are added at the early stages of aggregation they promote the formation of 
unstructured, off pathway A aggregates (blue pathway). When mature A fibrils are treated 
with DLPC LUVs, the lipid induces a polymorphic change within the fibril without significantly 
altering the cross -strand structure of the fibril, resulting in a more protofibrillar structure in the 
final aggregates (red pathway). 
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chain orientation of mature fibrils. Interestingly, a lipid bilayer composed of dilauroyl 
phosphatidylserine (DLPS), which shares the acyl chain length and hydrophobic thickness of 
DLPC, has been shown to promote the aggregation of -synuclein, an amyloid implicated in 
Parkinson’s disease.67 This finding suggests that the inhibition of A aggregation by DLPC may 
be dependent on peptide, lipid head group, or possibly both. It is essential that the functions of 
thin bilayers of more varied complexity are explored to clarify their functions within a biological 
context. Additionally, it will be valuable to further explore the universality of DLPC mediated 
inhibition of amyloid formation. If DLPC serves as a universal amyloid inhibitor, it may become 
a powerful tool in the examination of amyloid structure and function for its ability to remodel 
aggregates without dissociation by high concentrations of harsh chemicals or detergents (Fig. 
4.5c). 
4.4. Methods 
4.4.1. Materials  
 All reagents were purchased from commercial suppliers and used as received unless 
noted otherwise. A was purchased from BioBasic (Markham, ON, Canada) (A1-40= 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV) at >95% purity and used 
without further purification. All lipids were purchased from Avanti Polar Lipids Inc. (Alabaster, 
AL, U.S.A.). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, U.S.A). 
Detailed experimental descriptions are included in SI Text. 
4.4.2. Vesicle preparation 
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 Large unilamellar vesicles (LUVs) of DLPC, DOPC, and POPC were prepared from 
stock chloroform solutions. The resulting solution was dried under a nitrogen stream and placed 
under vacuum overnight to remove residual solvent. The resultant lipid film was rehydrated in 
buffer (20 mM PO4, pH 7.4, 50 mM NaCl) to yield a final lipid concentration of either 1 mM, 10 
mM, or 24 mM (for solid-state NMR experiments). Dried lipid was resuspended by vortexing the 
solution and was subsequently extruded via 23 passes through a polycarbonate Nucleopore 
membrane filter (either 50, 100, 400 or 1000 nm, depending on experiment; Whatman) mounted 
to a mini-extruder (Avanti Polar Lipids Inc.) to obtain a homogeneous solution of LUVs. The 
formation of vesicles was subsequently confirmed by dynamic light scattering to ensure 
homogeneity. 
4.4.3. Peptide preparation 
 A was received having been treated with hexafluoroisopropanol intended to 
monomerize the peptide. To disrupt any remaining aggregates, A was dissolved in 5% v/v 
NH4OH at a concentration of 0.5 mg/mL. The peptide was aliquoted into 0.1 mg samples and 
lyopohilized overnight and stored at -20 C until they were needed for an experiment. To prepare 
monomeric A for experimentation, peptide was dissolved in buffer (20 mM PO4, pH 7.4, 50 
mM NaCl) to a final concentration of 120 M. The stock solution as sonicated for 10 s and then 
used immediately after preparation. 
4.4.4. Thioflavin-T (ThT) assay 
 The kinetics of amyloid formation were monitored by the fluorescent, amyloid-specific 
dye ThT. Samples were prepared by diluting the 120 M A stock to a final concentration of 10 
M in the presence of 20 M ThT. To this was also added lipid from the prepared stock at a 
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concentration ranging from 100 nM to 1 mM. Samples were plated in triplicate on Corning 96-
well plates, maintained at 25 C, and subject to continuous, slow orbital shaking. Fluorescence 
readings were taken on a Biotek Synergy 2 microplate reader using Corning 96 well plates. 
Wells were read from the bottom with an excitation wavelength of 440 nm (30 nm bandwidth) 
and an emission wavelength of 485 nm (20 nm bandwidth) at three minute intervals.  
 After data acquisition, raw fluorescence values were background subtracted and then 
normalized. Normalized curves were then individually fit to Eq. 1 and Eq. 2 in order to calculate 
the individual lag phase (tlag) for each curve.
48
 These values were then averaged across three 
separate trials. 
𝐹(𝑡) = 𝐹𝑖𝑛𝑓 +
𝐹0 − 𝐹𝑖𝑛𝑓
(1 +  𝑒𝑘(𝑡−𝑡50))
 
(1) 
𝑡𝑙𝑎𝑔 = 𝑡50 −
2
𝑘
 
(2) 
 For studies exploring fibril remodeling, fibrils were initially formed in the 96-well plate for 
24 h. After mature fibrils were formed, lipid (either in LUVs or as free lipid) was added directly 
to wells at varying concentrations, diluting the volume by less than 1% to maintain signal 
intensity. The experiment was then restarted under identical conditions to those used to monitor 
fibril formation. 
4.4.5. Circular dichroism (CD) 
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 Single point CD measurements were carried out at a concentration of 30 M Ain the 
absence or presence of 300 M (10 equiv) 100 nm LUVs of either DLPC, DOPC, or POPC in 
buffer (20 mM PO4, pH 7.4, 50 mM NaF). CD measurements were performed on a JASCO J-
1500 CD Spectrometer using a 0.1 cm path length cell. Spectra were acquired at 25 °C using a 
bandwidth of 2nm, a scan rate of 200 nm/min, and averaging spectra over 20 scans. 
Measurements were taken immediately after mixing the sample (t = 0 h) and after 24 h 
incubation at 25 °C under slow orbital shaking (conditions mimicking those used in ThT kinetic 
assays). 
 For time course analysis of fibril remodeling, fibrils were initially formed at 30 M in 
buffer by incubating for 24 h at 25 °C under slow orbital shaking. After formation of the mature 
fibrils, LUVs were added to the solution and the CD spectrum was monitored over time. In 
between reads, the sample was maintained at 25 °C under slow orbital shaking. 
4.4.6. Transmission electron microscopy (TEM) 
 Samples used in TEM analysis were taken directly from the time course CD experiments 
after 24 h incubation (both for the modulation of fiber formation and the remodeling of 
preformed fibrils). Glow discharged grids (Formar/carbon 300 mesh, Electron Microscopy 
Sciences, Hatfield, PA, U.S.A.) were treated with samples (5 L) for 2 min at room temperature. 
Excess buffer was removed via blotting and then washed three times with ddH2O. Each grid was 
then incubated with uranyl acetate staining solution (1% w/v in ddH2O, 5 L) for 1 min, and 
excess stain was blotted away. Images from each sample were taken on a JEOL 1400-plus TEM 
(80 kV) at 50,000x magnification. 
4.4.7. Atomic force microscopy (AFM) 
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 Supported lipid bilayers (SLBs) of POPC, DOPC and DLPC were deposited on fleshly 
cleaved mica by immersion of the substrates in vials containing the lipid vesicle dispersions in 
phosphate buffer saline solution (PBS, 10 mM, pH=7.4 at 25°C), kept in a sonication bath for 1 
h. AFM images were acquired with a Cypher S (Asylum Research, Oxford Instruments) 
microscope in liquid AC mode using rectangular-shaped Si3N4 cantilever tips (BL-RC-150VB, 
Olympus, Tokyo, Japan) with a nominal spring constant of 0.03 N/m.  
4.4.8. 
31
P solid-state NMR 
 Experiments were performed on a Varian 600 MHz solid-state NMR spectrometer. A 
Varian temperature control unit was used to maintain the sample temperature at 30 °C. All 
31
P 
spectra were collected using a single pulse under 42 kHz two-pulse phase modulation decoupling 
of protons. A typical 90 pulse length of 6.0 s was used with a recycle delay of 3 s. The 31P 
chemical shift spectra are referenced with respect to 85% H3PO4 at 0 ppm. In each experiment, 
the 
31
P spectrum of 200 L of 1000 nm LUVs composed of 23 mM DLPC, DOPC, or POPC was 
first acquired in the absence of peptide in buffer (20 mM Hepes, pH 7.4, 50 mM NaCl). After 
acquisition of the control spectrum, A was added to the lipid solution at a concentration of 230 
M (100:1 lipid-peptide ratio) and the sample was incubated at 25 °C under slow orbital shaking 
for 24 h to induce aggregation. Following aggregation, a 
31
P spectrum was again acquired for 
each sample. Each spectrum is the result of 20,000 scans.  
4.4.9. 
1
H NMR 
 Experiments were performed on a Bruker 600 MHz NMR spectrometer equipped with a 
cryoprobe. A 1D 
1
H spectrum of monomeric A (50 mM) was initially acquired in buffer (20 
mM PO4, pH 7.4, 50 mM NaCl, 10% v/v D2O). Peptide aggregation was then induced by 
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constant orbital shaking at 25 °C for 24 h. A spectrum was again taken of this aggregated 
sample. 100 nm DLPC LUVs were then added to the preformed aggregate sample (500 M 
lipid) and acquisitions were taken continually for 23 h. Each spectrum was acquired at 25 °C and 
is the combination of 128 total scans. All spectra are normalized with respect to the initial 
monomer acquisition. 
4.4.10. Thermal denaturation 
 Four types of amyloid fibrils of 20 μM A in 20 mM sodium phosphate buffer (pH 7.4) 
containing 50 mM NaCl prepared with constant shaking (50-sec shaking – 10-sec quiescence) at 
37 °C, were used for CD measurements. A amyloid fibrils, which grew spontaneously from A 
monomer solutions for 24 h without DLPC LUVs, were immediately used for CD measurements 
after confirming the stationary phase of fibrillation after the lag and exponential phase based on 
ThT fluorescence-based kinetics. The other three types of A amyloid fibrils were obtained after 
a further 16 h incubation in the absence and presence of DLPC LUVs (100 μM and 400 μM 
DLPC) at 37 °C with the same shaking cycle above.   
 Heat scanning of all types of A amyloid fibrils from 25 to 110 °C was performed by 
monitoring CD signals at 220 nm at a rate of 10 °C per minute. CD measurements were 
performed with a J-820 spectropolarimeter (Jasco, Japan) equipped with a water-circulating cell 
holder for temperature control. Temperature was regulated using a PTC-423L Peltier-unit (Jasco, 
Japan). A cell with a light path of 1 mm was sealed with a lid to prevent solvent evaporation 
during the heat treatment. CD signals were expressed as the mean residue ellipticity [θ] (deg cm2 
dmol
-1
). 
128 
 
 The melting temperature (Tm) and the enthalpy change (H) of heat denaturation of A 
amyloid fibrils were determined by a regression analysis using a nonlinear least squares fitting of 
data to the sigmoidal equation (3) under the assumption of a two-state transition between 
unfolded monomers and amyloid fibrils. It should be noted that we performed thermodynamic 
analyses although thermal denaturation of A amyloid fibrils was irreversible.  
  =  
(𝑎 –  𝑐) + (𝑏 –  𝑑)𝑇
1 + exp (–
Δ𝐻(𝑇m)
𝑅 (
1
𝑇 – 
1
𝑇m
)  +  
Δ𝐶p
𝑅 (
𝑇m
𝑇 – 1 +  ln
𝑇
𝑇m
))
 +  (𝑐 +  𝑑𝑇) 
  (3) 
where θ is the signal intensity monitored by CD. The pre- and post-unfolding baselines are 
described by a + bT and c + dT. T and R indicate temperature and gas constant, respectively. The 
change in heat capacity is shown by Cp. Details of the derivation of the equation above are 
provided below. In our derivation, we assumed the two-state thermal denaturation model since 
the irreversible process in the Lumry-Eyring model can be neglected due to the high scan rate of 
10 °C per minute used.
68,69
 
4.4.11. Derivation of the fit equation for thermal denaturation 
A model of the two-state thermal denaturation of A amyloid fibrils is defined as: 
F  U 
(4) 
where F and U indicate the fibrillar and unfolded (i.e. denatured) states of A, respectively. 
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The equilibrium constant of the unfolding reaction (KU) is given by the ratio of the fraction of 
each conformational state: 
𝐾U  =  
𝑓U
𝑓F
 
(5) 
where fF and fU represent the fraction of A in the fibrillar and unfolded conformations, 
respectively. 
The fraction is expressed as follows: 
𝑓F  +  𝑓U = 1 
(6) 
Combining equations 4 and 5 gives: 
𝑓F  =  
1
1 +  𝐾U
 
(7) 
𝑓U  =
𝐾U
1 +  𝐾U
 
(8) 
The observed CD intensity (θ) of A at a given temperature is expressed as: 
  =  𝑓F(𝑇)𝜃F  +  𝑓U(𝑇)𝜃U 
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(9) 
where fF(T) and fU(T) are the fibrillar and unfolded fractions of A at a given temperature (T), 
respectively. θF and θU indicate the CD signals of fibrillar and unfolded of A, respectively. 
Using equations 7 and 8, equation 9 becomes: 
  =  
1
1 +  𝐾U
𝜃F  +  
𝐾U
1 +  𝐾U
𝜃U 
(10) 
Rearranging equation 7 gives: 
   =  
𝜃F – 𝜃U
1 +  𝐾U
 +  𝜃U 
(11) 
θF and θU are CD signals of fibrillar and unfolded A, respectively, over a certain temperature 
range and are expressed as follows: 
𝜃F  =  𝑎 +  𝑏𝑇 
(12) 
𝜃U  =  𝑐 +  𝑑𝑇 
(13) 
where a + bT and c + dT are the baselines of pre- and post-unfolding. a and c are intercepts and b 
and d are slopes. 
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Substituting equations 12 and 13 into equation 11 gives the following equation: 
  =  
(𝑎 +  𝑏𝑇) – (𝑐 +  𝑑𝑇)
1 +  𝐾U
 +  (𝑐 +  𝑑𝑇) 
(14) 
This is rearranged to the following equation: 
  =  
(𝑎 –  𝑐)  +  (𝑏 –  𝑑)𝑇
1 +  𝐾U
 +  (𝑐 +  𝑑𝑇) 
(15) 
The change in enthalpy, ΔH(T), and entropy, ΔS(T), for the thermal denaturation of A amyloid 
fibrils at a certain temperature is expressed as follows: 
Δ𝐻(𝑇)  =  Δ𝐻(𝑇m)  +  ∫ Δ𝐶p
𝑇
𝑇m
d𝑇 
(16) 
Δ𝑆(𝑇)  =  
Δ𝐻(𝑇m)
𝑇m
 +  ∫ Δ𝐶pln𝑇
𝑇
𝑇m
d𝑇 
(17) 
where Tm is the midpoint temperature of the thermal denaturation of A amyloid fibrils and ΔCp 
is the heat capacity change between fibrillar and unfolded A. 
Equations 16 and 17 are solved as follows: 
Δ𝐻(𝑇)  =  Δ𝐻(𝑇m)  +  Δ𝐶𝑝(𝑇 – 𝑇m) 
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(18) 
Δ𝑆(𝑇)  =  
Δ𝐻(𝑇m)
𝑇m
 +  Δ𝐶pln
𝑇
𝑇m
 
(19) 
The temperature dependence of the change in Gibbs free energy, ΔG(T), at a certain temperature 
is defined by the following equations: 
Δ𝐺(𝑇)  = – 𝑅𝑇ln𝐾U 
(20) 
Δ𝐺(𝑇)  =  Δ𝐻(𝑇)  –  𝑇Δ𝑆(𝑇) 
(21) 
where R is the gas constant. 
Equation 20 may be rearranged for KU: 
𝐾U = exp (–
Δ𝐺(𝑇)
𝑅𝑇
) 
(22) 
where “exp” means an exponential function. 
Substituting equation 22 into equation 15 gives: 
   =  
(𝑎 –  𝑐)  +  (𝑏 –  𝑑)𝑇
1 +  exp (–
Δ𝐺(𝑇)
𝑅𝑇 )
 +  (𝑐 +  𝑑𝑇) 
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(23) 
Substituting equations 18 and 19 into equation 21 gives: 
Δ𝐺(𝑇)  =  (Δ𝐶p(𝑇 – 𝑇m))  –  𝑇 (
Δ𝐻(𝑇m)
𝑇m
+   Δ𝐶pln
𝑇
𝑇m
) 
(24) 
Equation 24 is rearranged to yield the following equation: 
Δ𝐺(𝑇)  =  Δ𝐻(𝑇m) (1 – 
𝑇
𝑇m
) –  Δ𝐶p (𝑇m –  𝑇 +  𝑇 ln
𝑇
𝑇m
) 
(25) 
Substituting equation 25 into equation 23 gives: 
   =  
(𝑎 –  𝑐)  +  (𝑏 –  𝑑)𝑇
1 + exp (–
Δ𝐻(𝑇m) (1 – 
𝑇
𝑇m
) –  Δ𝐶p (𝑇m –  𝑇 +  𝑇ln
𝑇
𝑇m
)
𝑅𝑇 )
 +  (𝑐 + 𝑑𝑇) 
(26) 
Equation 25 is rearranged to yield the final equation: 
   =  
(𝑎 –  𝑐) + (𝑏 –  𝑑)𝑇
1 + exp (–
Δ𝐻(𝑇m)
𝑅 (
1
𝑇 – 
1
𝑇m
)  +  
Δ𝐶p
𝑅 (
𝑇m
𝑇 – 1 +  ln
𝑇
𝑇m
))
 +  (𝑐 +  𝑑𝑇) 
(3) 
4.4.12. Cellular culture and cytotoxicity analysis 
134 
 
 PC12 cells were grown in RPMI-1640 media without L-glutamine supplemented with 5% 
fetal bovine serum, 10% horse serum, and 1% penicillin-streptomycin, in a humidified incubator 
at 37 °C with environment of 5% CO2. Cells were kept between passage numbers 20-35. 10 cm 
cell culture dishes were used for culturing, and 96 flat bottom well trays for the MTT assays. 
Cells in a suspension of 90 L (total of 104 cells) were dispensed in each well and allowed to 
adhere for 1 day before adding peptide aggregates. 
 Peptide aggregates were generated by incubating A (25 M) in the absence or presence of 
100 nm DLPC LUVs (1-10 equiv) for 18 h at 25 °C in buffer (20 mM PO4, pH 7.4, 50 mM 
NaCl). Aggregates were taken prior to complete fibrillation due to the purported toxicity of the 
intermediate aggregates.
3,70
 10 L of aggregate solution was then added to the plated PC12 cells 
to a final volume of 100 L (2.5 M A). After 24 h incubation of cells with aggregates, the 
MTT cell proliferation assay (Promega, G4000) was used to determine the toxicity of samples 
following the manufacturer protocol. 15 L of the MTT dye solution was added to each well and 
set to incubate at 37 °C for 3-3.5 h. 100 L of solubilization/stop buffer was added and set to 
incubate for 2-3 h. The absorbance of each well as then measured at both 570 nm and 700 nm 
(700 nm for background correction). All cellular viability values were normalized to cells treated 
with buffer. Values reported are the average of three independent trials and the error is reported 
as the standard deviation of these averages. 
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Chapter 5 
Conclusions and Perspectives 
5.1. General Conclusions 
 The multivariate nature of AD makes it difficult to characterize the impact which 
individual molecular and cellular components have upon the disease’s presentation and 
progression.
1-3
 Previous research has suggested that metal ion dyshomeostasis, the resultant 
oxidative stress, and neuronal membranes are all capable of perturbing the aggregation of 
Acommonly associated with AD. The roles of metal-A aggregation in AD remain clouded 
due to a lack of effective tools to interrogate individual aspects of the fibrillation pathway.
4,5
 
Meanwhile, investigations of membrane-associated aggregation have done little to investigate 
the role of disease relevant membrane parameters outside the role of GM1 ganglioside.
6,7
 
Through a combination of biochemical and biophysical approaches we have characterized the 
effects of new series of natural product small molecules and their synthetic derivatives on the 
aggregation of A in both the absence and presence of metal ions in pursuit of new molecular 
tools. Additionally, we have characterized the effect of lipid membrane thinning, a phenomenon 
resulting of lipid peroxidation,
8-10
 on A aggregation. The results of these studies have provided 
new insights into multifunctional ligand design and suggest previously undiscovered pathways of 
peptide aggregation on lipid bilayers. 
 Results in Chapter 2 differentiate the modulation of metal-A by a suite of three 
previously identified amyloid modulators (Phlorizin, Verbascoside, and Rutin) and the effect 
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of esterification on their function and stability. It was observed that only compounds with the 
conventional bidentate metal binding catechol moiety were capable of significantly modulating 
aggregation in the presence of metal ions. Additionally, esterification of the compounds altered 
the method of aggregation modulation but did not significantly impact their capacity to bind 
metal ions. Esterification also redirected the modes of interaction between the compounds and 
both monomeric and fibrillar A, but minimally affected the affinity. Finally, by altering the 
modes of inhibition and peptide binding, esterification significantly altered the ability of the 
compounds to inhibit the toxicity of A aggregation. The results suggest that, while these 
molecules, particularly Verbascoside, demonstrate extremely promising structures for the future 
study of A aggregation, modifications of the framework must be performed selectively so as 
not to reduce the molecule’s functionality. Additionally, due to the presence of the catechol 
moieties of Verbascoside which are responsible for driving the interaction with transition metal 
ions, care must be taken in any implementation of the compound in a more complex 
environment. These pharmacophores are known to promiscuously drive a range of non-specific 
interactions with proteins and are especially prone to oxidation in cells and in vivo.
11
 Further 
optimization of the framework may generate a more stable and specific probe for further study, 
but Verbascoside, in its current state, is a viable tool for the continued in vitro characterization 
of metal-A aggregation.  
 Chapter 3 represents a change of direction; instead of developing new tools for 
interrogation of metal-A aggregation, we applied existing tools and methodologies to 
investigate the interaction of A with lipid bilayers of varying thickness. It has been suggested 
previously that A adopts a helical fold when bound to lipid bilayers, though all previous 
structural insight with residue specific resolution into these interactions were obtained in the 
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presence of micelles, a poor mimetic of a lipid bilayer.
12-14
 Traditionally, when an amyloidogenic 
peptide binds to the membrane, its signal in solution NMR spectroscopy broadens due to the 
decreased tumbling rate of the peptide-lipid complex and the introduction of one or more new 
populations of peptide.
15,16
 We took advantage of the exchange between the unbound and bound 
populations of A to interrogate the structural constraints of the bound peptide without a 
significant reduction in signal intensity using solution NMR. Transfer-NOESY (tr-NOESY) has 
previously been applied to investigate the interaction of small molecule ligands with their protein 
partners and small peptide binding to larger species.
17-21
 Here, we applied the same methodologie 
to examine the exchange between free peptide and peptide bound to three different model 
membranes. Our results represent the largest binding species characterized by tr-NOESY to date. 
Based on the observed NOEs and chemical shift results, we identified a partially folded helical 
intermediate adopted in the presence of all three lipid bilayers. This result suggests that the initial 
folding event when A interacts with a lipid bilayer is driven predominantly by the surface 
environment and is independent of the hydrophobic thickness and acyl chain characteristics of 
the lipid bilayer. Additionally, the helical region which was identified (K16-G25) is also 
implicated in the early self-association events in amyloid formation and forms one of the -
strands observed in fibrillar structures.
1
 This region has also been suggested to adopt a helical 
structure in a soluble, folded model of A40.
22
 The prevalence of this sequence appearing in a 
variety of structural forms at different stages of aggregation strongly supports the hypothesis that 
it plays a driving role in many of the aggregation events. Interestingly, the hydrophobic thickness 
did modulate the affinity of the peptide for the lipid bilayer and the distribution between bound 
and unbound A; the thicker the bilayer the tighter the affinity which was observed. This 
suggests that either bilayer thickness controls the distribution of free and bound peptide without 
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modulating the monomeric structure or bilayer thickness regulates the progression of A from its 
monomeric form towards intermediate aggregates as those distinctions were not able to be made 
based on our fluorescence-based binding study. 
 The differences in the equilibrium between bound and unbound A populations regulated 
by the membrane hydrophobic thickness made us begin to question how bilayer thinning may 
impact the progression of A from its conserved, partially folded state towards mature amyloid 
fibrils (Chapter 4). It is known that A is capable of forming membrane-inserted oligomeric 
species.
23-25
 Additionally, it is known from the field of membrane proteins that hydrophobic 
match and mismatch between the bilayer and the inserted protein is able to regulate the stability 
distinct the inserted protein.
26,27
 We expected, therefore, that the observed differences in 
membrane association result from the stabilization or destabilization of distinct membrane 
inserted oligomers which could be on or off pathway. While the membranes of traditional 
thickness, DOPC and POPC, promoted canonical A fibrillation, as has been previously 
reported,
28,29
 we found that substoichiometric concentrations of DLPC, a synthetic mimic of the 
membrane thinning associated with AD, were sufficient to completely inhibit the fibrillation of 
A. Through a combination of ThT-fluorescence, CD spectroscopy, and microscopy, we 
discovered that DLPC bilayers stabilized globular, membrane associated oligomers which were 
not observed to progress towards fibrils. Additionally, oligomer formation on the membrane 
surface produced micelle-like lipid aggregates which have the potential to serve as a second sink 
for non-fibrillar A aggregates. DLPC bilayers were also found to be capable of remodeling 
preformed A fibrils by stabilizing a pseudo-unfolded intermediate state which resembles 
protofibrillar assemblies. These results indicate that alterations to membrane composition and 
structure resulting from metabolic alterations in AD are capable of redirecting the misfolding of 
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membrane-associated A into unique oligomeric states. These sorts of stabilized intermediates 
have not been previously reported and may represent a new, disease relevant aspect of A 
aggregation. 
5.2. Future Outlook  
 The work presented in this dissertation has characterized tools with the potential to 
inform our broader understanding of amyloid misfolding in both AD and other disease states. 
Metal ion-modulated aggregation is not unique to A and AD. Zn(II) is known to modulate the 
aggregation of hIAPP associated with type II diabetes while -synuclein, implicated in the 
pathogenesis of Parkinson’s disease, is known to interact with Zn(II), Cu(I/II), and Fe(II/III).30-32 
It is possible that small molecules which are found to modulate metal-A aggregation may have 
more wide ranging antiamyloidogenic activity against other metal-associated, amyloidogenic 
peptides and proteins. A lack of universal activity by a known modulator may also assist in 
distinguishing aspects of amyloid formation which are sequence specific. Protein aggregation 
into amyloid fibrils is often discussed as a single, common pathway,
33
 yet the diversity of 
sequences which can aggregate into fibrils suggests that there exist intermediate states between 
monomer and fiber which are unique to individual proteins. If a small molecule is capable of 
modulating the metal-associated aggregation of some proteins and not others, this supports this 
idea. Characterizing which small molecules are capable of modulating which aggregation 
pathways can help identify aspects unique to each amyloidogenic sequence. By characterizing 
the unique aspects of amyloid formation it may be possible to begin to treat amyloid formation as 
a more diverse pathway than it currently is. 
146 
 
 Despite the conclusions of Chapter 4 suggesting that DLPC remodels preformed A40 
fibrils by stabilizing a molten-globule-like intermediate, there remains a lack of structural data to 
suggest just how such an intermediate may be stabilized for A40 or any other amyloid fibril.
34
 
While changes in stability have been attributed to side chain perturbations, which side chains are 
most affected (whether they form the steric zipper on the interior or the fiber are solvent 
exposed) and the ways in which they are affected remain unknown. As discussed in Chapter 4, 
structural analysis of amyloid aggregates is made difficult by the presence of sample 
heterogeneity. Immediately following DLPC-induced remodeling it is likely that a variety of 
aggregate states exist. However, it has been demonstrated that molten-globule-like remodeled 
fibrils are capable of seeding fiber formation.
34
 Additionally, seeding is known to propagate seed 
structure.
35
 Through a combination of these two methods, it may be possible to generate a 
homogeneous population of A40 aggregates which possess the DLPC-remodeled side chain 
arrangement. With a homogeneous population in hand, solid-state NMR methods could 
subsequently characterize these altered aggregates at atomic resolution. These data would further 
characterize the mechanism by which ThT functions, which remains uncertain, while also 
helping clarify which side chains are most integral for A fiber stability and which are most 
susceptible to perturbation by environmental changes. 
 While identifying oligomeric intermediates along the amyloid formation pathway is 
essential to solving the black box that exists between monomeric peptide and fibrillar aggregate, 
structurally characterizing them remains a daunting task. Oligomer identification has been 
possible, but the transient and unstable nature of their formation has limited their structural 
analysis.
36
 In this respect, the use of lipid bilayers can become a powerful tool. While 
membranes are usually considered a complicating factor in A aggregation, the results of 
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Chapter 4 have revealed that the careful selection of membrane composition can stabilize non-
fibrillar aggregates stabilized by the presence of the lipid bilayer. Additionally, the ongoing 
developments of lipid nanodisc technology, constrained lipid bilayer systems with a finite 
surface area and highly customizable composition, has expanded the techniques available for the 
study of membrane proteins and protein complexes formed in the lipid bilayer.
37-39
 Nanodiscs 
facilitate structure determination of traditional membrane proteins by solution NMR.
37
 More 
recently, the investigation of protein-protein complexes formed in native membrane 
environments has been facilitated by isotropic nanodiscs.
40
 Additionally, nanodiscs have enabled 
FRET-based structural analysis of a dimer formed by the non-amyloidogenic rat variant of 
IAPP.
41
 Despite the advantages of nanodiscs in the structural study of membrane-associated 
proteins and protein complexes, they remain relatively unexplored in the study of amyloid 
oligomer formation. Combining this technology with our current understanding of how 
pathological membrane compositions can modulate the formation of A intermediates, it may be 
possible to not only identify unique aggregation intermediates but also to generate structural 
models of them. With structural insights in hand, the rational design of small molecule 
modulators, with an eye towards eventual therapeutic development, ought to be improved. By 
better understanding the misfolding pathways of A in AD it may be possible to reduce the toll 
which the disease places on world economies, health care industries, caregivers, families, and 
those who suffer from the disease. 110 years after the first descriptions of AD, patients are ready 
for progress. 
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Appendix A 
Supporting Information for Chapter 2 
A.1. Supplementary Figures 
 
 
Figure A.1. Visualization of the morphologies of the resultant A species from the 
disaggregation samples that were incubated with Phlorizin or R2 for 24 h by TEM. Conditions: 
[A] = 25 M; [CuCl2 or ZnCl2] = 25 M; [compound] = 50 M; incubation for 4 or 24 h; pH 
6.6 (for Cu(II) samples) or pH 7.4 (for metal-free and Zn(II) samples); 37 °C; constant agitation. 
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Figure A.2. Effect of Phlorizin, F2, Verbascoside, VPP, Rutin, or R2 on the formation of 
metal-free and metal-induced A40/A42 aggregates. A40
 
(a) and A42 (b) were co-incubated 
with or without compound in both the absence and presence of either CuCl2 or ZnCl2 for either 4 
or 24 h and visualized by gel/Western blot. Conditions: [A] = 25 M; [CuCl2 or ZnCl2] = 25 
M; [compound] = 50 M; 4 or 24 h incubation; pH 6.6 (for Cu(II) samples) or pH 7.4 (for 
metal-free and Zn(II) samples); 37 °C; constant agitation. 
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Figure A.3. Cu(II) binding studies of Phlorizin (Phlo), F2, Rutin, and R2 by UV-Vis. 
Compounds were dissolved in buffer at pH 7.4 and titrated with Cu(II) and incubated for 2 h 
between reads. Experimental condition: [compound] = 25 M; incubation for 2 h; room 
temperature. 
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Figure A.4. Zn(II) binding of non-phenolic protons of Verbascoside and VPP. Samples of (a 
and b) Verbascoside and (c and d) VPP were dissolved in DMSO-d6 (2 mM) and titrated with 
ZnCl2 (0-10 equiv). Broadening or shifts of protons in the aromatic region (a and c) and the sugar 
ring region (b and d) of the 
1
H spectra were not observed over the course of the titration. 
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Figure A.5. Interaction of Phlorizin or R2 with monomeric A40 by SOFAST-HMQC NMR. (a) 
Phlorizin or (b) R2 was titrated into a solution of uniformly 
15
N-labeled A40 (80 M in 20 mM 
PO4, pH 7.4, 50 mM NaCl, 7% v/v D2O, 10 °C). The spectrum obtained upon incubation of A40 
with 10 equiv of the ligand was indicated in blue; the spectrum of A40 only was depicted in red. 
All spectra were aligned at G29 due to non-uniform broadening of the water peak as a reference. 
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Figure A.6. Affinity and competition of Verbascoside and VPP for A42 fibrils. The affinity of 
(a) Verbascoside and (b) VPP for A fibrils was measured by a blue shift fluorescence assay. 
The data were fit to a hyperbolic function to calculate the affinities (red line). The ligands were 
then tested for binding competition by STD. The relative intensity of the selected peaks in the 
STD spectra (relative to the reference spectra) were monitored over the course of a titration of (c) 
Verbascoside into the fibrils pretreated with VPP; (d) VPP into the fibrils pretreated with 
Verbascoside. 
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Figure A.7. Cytotoxicity of Verbascoside (Verb), VPP, and Rutin in the absence and presence 
of CuCl2 or ZnCl2. N2a cells treated with a metal chloride salt (CuCl2 or ZnCl2; 5 M, 10 M, or 
25 M) and a compound [Verbascoside, VPP, or Rutin (5 M, 10 M, or 25 M)] were 
incubated for 24 h at 37 °C. Cell viability was determined by the MTT assay. Values of cell 
viability (%) were calculated compared to that of cells treated with DMSO only (0-1%, v/v). 
Error bars represent the standard error from three independent experiments.  
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Appendix B 
Supporting Information for Chapter 3 
B.1. Supplementary Figures 
 
 
Figure B.1. Conformational analysis of A40 upon incubation with lipids for at least 24 h by CD. 
When A40 (20 M) was co-incubated with 0.2 equiv (4 M) LUVs composed of (a) DLPC, (b) 
DOPC, or (c) POPC at different time intervals. The random coil structure persisted in the 
presence of all three bilayers over the experimental timescale of 24 h.  
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Figure B.2. Effect of LUVs on lipid-bound and –unbound states of peptide. A40 undergoes a 
fast-mediate exchange in the presence of substoichiometric lipid concentrations. The amide and 
aromatic regions of the 
1
H region of A40 (80 M) NMR spectra broaden in the presence of low 
concentrations of LUVs (14 M lipid; colored spectra) relative to the lipid-free spectra (black), 
indicative of an exchange between lipid-bound and -unbound states of the peptide. 
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Figure B.3. Paramagnetic quenching of the peptide signal. A solution of uniformly 
15
N-labeled 
A40 (80 M) in the presence of LUVs (0.2 equiv, 16 M) containing either (a) DLPC, (b) 
DOPC, or (c) POPC was titrated with a solution of MnCl and the residue signal intensity was 
monitored by 2D SOFAST-HMQC (Bruker 600 MHz spectrometer, equipped with cryoprobe at 
10 C). The quenching of residue specific signal is indicative of exposure to buffer while 
maintenance of the initial intensity suggests the membrane interaction and protection from 
paramagnetic quenching. 
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Figure B.4. Binding affinities of A40 to lipid bilayers based on fluorescence polarization. 100 
nm LUVs (DLPC, DOPC, and POPC) were titrated into 1 M HiLyte 647-A40 and the 
fluorescence polarization was monitored. Anisotropy values were converted to fraction bound 
and fit to obtain binding affinities of A40 for the various bilayers. 
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Figure B.5. Correlation between backbone flexibility and membrane affinity. There is a linear 
correlation between the average R2 and the binding affinity of the A40 peptide in the presence 
of each bilayer. The R2 experiments of A40 with and without LUVs were performed on a Bruker 
600 MHz spectrometer at 10 C. The tighter the binding affinity (Kd) indicates the larger the 
R2, indicative of the reduced ensemble flexibility. 
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Appendix C 
Supporting Information for Chapter 4 
C.1. Supplementary Figures 
 
Figure C.1. A aggregate secondary structure and morphology. (a) A (30 M) fibrils grown for 
24 h in the absence and presence of DOPC, POPC, or DLPC LUVs (300 M lipid) were 
compared to freshly prepared, monomeric A by CD. (b) TEM images were acquired of the end 
stage aggregates after 24 h incubation for each sample used in CD analysis. 
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Figure C.2. Role of liposome curvature on DLPC inhibitory activity. LUVs of (a) 50 nm, (b) 
400 nm, and (c) 1000 nm were incubated with monomeric A(10 M) at varying concentrations 
under aggregation promoting conditions. The kinetics of aggregation were monitored by ThT (20 
M) and the averages of three independent traces are presented. Conditions noted by * exhibited 
lag phases longer than 24 h which could not be fit within the experimental constraints. (d) 
Individual aggregation curves were fit to calculate the lag phase of aggregation as a function of 
DLPC concentration for all three LUV sizes. Values presented represent the average lag phase 
from three independent trials; error bars represent the standard deviation of three separate 
experiments. 
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Figure C.3. Efficacy of free DLPC. (a) ThT probed the dose dependent ability of free DLPC to 
modulate the fibrillation of A. Curves represent the average of three independent traces. (b) 
Individual aggregation curves were fit to calculate the lag phase of aggregation as a function of 
free DLPC concentration. Values presented represent the average lag phase; error bars represent 
the standard deviation of three separate experiments. Conditions noted by * exhibited lag phases 
longer than 24 h which could not be fit within the experimental constraints. (c) Free DLPC was 
added to preformed fibrils after 24 h incubation and the change in ThT fluorescence was 
monitored as a function of time. 
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Figure C.4. AFM on DLPC SLBs at early time points. AFM measurements of the same 5 x 5 
m region of a DLPC SLB were taken at early time intervals. 
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Figure C.5. Monomer observation during fiber remodeling. (a) The 1D 
1
H spectrum of freshly 
prepared A (50 M) was observed prior to fibrillation. After 24 h, the fibrillar sample was 
again observed prior to the addition of DLPC LUVs (500 M). (b) The 1D 1H spectrum was 
subsequently observed at 8 minute intervals for 23 h. The relative intensity (compared to freshly 
prepared monomeric A) of both the more flexible aromatic region (red) and the more rigid 
amide region (blue) were plotted versus time. The dark lines represent the moving average over a 
40 minute interval. 
 
 
 
 
 
 
 
 
